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Modification of MDMX by Ubiquitination and Sumoylation
Yu Pan
ABSTRACT

MDM2 and MDMX are two major negative regulators of tumor suppressor p53.
Both MDM2 and MDMX can inactivate p53 and play important roles in mouse
embryonic development in a p53 dependent manner. MDM2 possesses ubiquitin E3
ligase activity and mediates self-ubiquitination as well as ubiquitination and degradation
of p53 by proteasome. We identify MDMX as another ubiquitin E3 ligase substrate of
MDM2.

MDM2 promotes the ubiquitination and degradation of MDMX through

proteasome pathway. The RING domains of both MDMX and MDM2 are required and
sufficient for MDM2-mediated MDMX ubiquitination.

ARF overexpression, DNA

damage or MDM2 overexpression can all stimulate MDMX ubiquitination and
degradation. We present evidence that MDMX is also sumoylated. The sumoylation
sites on MDMX are identified. ARF N-terminus is required for stimulating both MDMX
ubiquitination and sumoylation. We also demonstrate that MDMX binds to ARF in an
MDM2-dependent fashion.

viii

Introduction

Tumorigenesis
The growth and proliferation of normal untransformed cells are the result of a
balanced relationship between oncogenes and tumor suppressors compared to those of the
tumor cells. Tumorigenesis is a progressive disease caused by the accumulative lesions
in the genome, producing either gain of function oncogenes or loss of function of tumor
suppressors, or both. The cancer cells are defective in their regulatory pathways, which
lead to the abnormal cell growth and proliferation. A vast majority of cancer cells
display a single or a combination of six traits: evasion from apoptosis, self-reliance in
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis,
unlimited replication potential and incessant angiogenesis (Friend, Bernards et al. 1986;
Hanahan and Weinberg 2000). While the uncurbed expression of oncogenes positively
regulates cell proliferation, tumor suppressors play important roles as genomic guardians
by restraining cell growth and proliferation, executing genetically impaired cells and
maintaining genomic stability. Rb was the first tumor suppressor isolated in human and
was found to be dysregulated in a majority of cancers (Friend, Bernards et al. 1986).
Another intensively studies tumor suppressor is p53, which plays pivotal roles in
maintaining homeostasis of the cells.

1

p53
p53 history
In 1979, p53 was originally recognized as a weak oncogene, which bound to the
simian virus (SV40) large T antigen and accumulated in the cancer cells (DeLeo, Jay et
al. 1979; Lane and Crawford 1979; Linzer and Levine 1979). Later, researchers found
that the oncogenic activity was caused by the gain-of-function mutant p53. By forming
tetramers with the wild type p53, mutant p53 suppresses wild type p53 function in a
dominant-negative fashion (Sigal and Rotter 2000). In 1990, it was found that the E6
oncoprotein encoded by human papillomavirus promotes the degradation of p53
(Scheffner, Werness et al. 1990). The fact that viral system developed specific
mechanisms using oncoproteins to target p53 for degradation underlines the importance
of p53 inactivation for virus survival and proliferation.
P53 belongs to a family of transcription factors including p53, p63 and p73.
While p63 and p73 take important responsibilities in maintaining normal development,
only p53 evolved to prevent tumor formation (Yang and McKeon 2000). Now it is
widely accepted that p53 is a classic tumor suppressor. P53 lost of function is found in
about 50% of all human tumors (Hollstein, Sidransky et al. 1991; Levine, Momand et al.
1991). Functional analysis revealed p53 as a potent stress responder regulating cell-cycle
arrest, DNA repair, cell senescence and apoptosis.

2

P53 function and transcription down stream targets
The structure of p53 represents a classic transcription factor (Ko and Prives
1996). It has transactivation domain in the N-terminus and the sequence-specific DNA
binding domain in the central region (fig 1). The DNA-binding domain contains hot
spots for mutation in tumor cells, indicating the tumor suppressor function of p53 relies
heavily on its transcriptional activity. P53 induces the transcription and over-expression
of a myriad of proteins through directly binding to their promoters, which leads to
various biological functions (fig 1). Although the number of genes found regulated by
p53 is still increasing, generally, these gene targets can be categorized into five groups
according to their functions: (1) Cell cycle arrest genes, (2) Apoptosis genes, (3) DNA
repair genes, (4) genes inhibiting angiogenesis and metastasis and (5) cellular senescence
genes.

Figure 1 Structure and functions of p53 tumor suppressor
3

(1) Cell cycle arrest genes: CDKs or cyclin-dependent kinases are a group of enzymes
evolved specifically to promote the cell cycle progression upon binding to correspondent
cyclin proteins, thus supporting the mitosis and division of the cells. CDK inhibitors, for
example, p16, p21 and p27, weigh the decision of going through S phase for DNA
synthesis. P53 directly promotes the transcription of p21, which inhibits the transition
from G1 to S and from G2 to M (el-Deiry, Tokino et al. 1993). 14-3-3 δ is another p53
transcriptional target that blocks the G2-M transition (Chan, Hermeking et al. 1999;
Laronga, Yang et al. 2000).
(2) Apoptosis genes: When DNA damage is beyond repair, apoptosis is the last
resolution to avoid the risk of having cells carrying damaged genetic signal and
proliferating. The apoptotic process can proceed through two main pathways: the
intrinsic and extrinsic pathways. The intrinsic pathway involves an apoptotic complex
called apoptosome that is comprised of mitochondria-released cytochrome c, Apaf-1 and
procaspase 9 (Kroemer and Reed 2000). The release of cytochrome c is a result of
mitochondria depolarization, a process under control by two groups of Bcl-2 family
proteins (Tsujimoto 2003). The proapoptotic group of proteins includes Bax and Bak
residing on mitochondrial membrane and the BH3 domain only proteins such as PUMA,
Noxa. The other group mainly contains anti-apoptotic Bcl-2 and Bcl-XL. The change in
ratio between the two groups determines the life or death of the cell.
One major tumor suppressive function of p53 is to induce apoptosis, thereby
preventing tumor cells from proliferating. P53 can transcriptionally induce proapoptotic
genes that participate in both intrinsic and extrinsic apoptosis pathways. In the intrinsic
4

pathway, p53 induces proapoptotic genes such as Bax, PUMA and Noxa, which localize
to the mitochondria and promote mitochondria depolarization (Miyashita, Krajewski et
al. 1994; Oda, Ohki et al. 2000; Nakano and Vousden 2001). As a result, cytochrome c is
released and the subsequent apoptosome formation and caspase activation eventually lead
to cell death. Another group of p53-induced genes belong to the death-receptor mediated
apoptosis pathway or extrinsic pathway, including DR5, Fas, PIDD.(Owen-Schaub,
Zhang et al. 1995; Wu, Burns et al. 1997; Muller, Wilder et al. 1998; Lin, Ma et al.
2000). Initiation of the extrinsic pathway results from ligand binding to the death
receptors, leading to the clustering of death receptors at the cell membrane and the
consequent induction of caspase activity. By transcriptionally activating proapoptotic
genes in both intrinsic and extrinsic pathways, p53 contribute significantly to apoptosis
and the disruption of p53 activity can lead to tumorigenesis.
P53 promotes apoptosis not only by transcriptional activation, but also through
transcriptional repression of the target genes. For instance, p53 represses the
transcription of survivin, which is an inhibitor of apoptosis (Ambrosini, Adida et al.
1997). Although p53 transcriptional repression is not as well understood as its
transactivation function, it is suggested that under certain circumstances, p53
transcription repression contributes more to apoptosis than does its gene transactivation
function (Koumenis, Alarcon et al. 2001).
Additionally, p53 can also induce apoptosis via transcriptional-independent
pathways (Caelles, Helmberg et al. 1994; Wagner, Kokontis et al. 1994; Haupt, Rowan et
al. 1995; Kokontis, Wagner et al. 2001; Dumont, Leu et al. 2003). Evidence showed that
the DNA-binding deficient p53 mutants could induce apoptosis almost as efficient as the
5

wild type. Furthermore, p53 regulates the intrinsic apoptotic pathway by directly
translocating to the mitochondria (Mihara, Erster et al. 2003; Mihara and Moll 2003). The
interaction between p53 and anti-apoptotic proteins such as Bcl-2 and Bcl-XL changes
the membrane integrity, leading to cytochrome c release and apoptosis. Additionally, it
has been reported that p53 promotes the transportation of Fas from cytoplasm to cell
membrane, augmenting the extrinsic pathway (Bennett, Macdonald et al. 1998).
(3) DNA repair genes: The defect in DNA repair genes will eventually lead to
genomic instability due to the accumulated errors in DNA left uncorrected. The
mechanism by which p53 mediates DNA repair remains elusive. However, experimental
data showed that P53 contributes to genomic stability by regulating the transcription of
DNA repair genes such as p48 and GADD45. (Kastan, Zhan et al. 1992; Smith, Chen et
al. 1994; Hwang, Ford et al. 1999).
(4) Genes inhibiting angiogenesis and metastasis: Angiogenesis is a hallmark for
tumorigenesis in solid tumors. In order for the tumor to progress and grow to a certain
size, ample blood supply is needed that can only be satisfied by the generation of new
blood vessels, or angiogenesis. Tumor cells shed into the blood vessels where they can
be carried to distant locations to metastasize. P53 promotes expression of genes to
antagonize tumor angiogenesis and metastasis processes. Some of the anti-angiogenesis
or anti-metastasis genes activated by p53 include MASPIN (Song, Lee et al. 2002), TSP1
(el-Deiry, Tokino et al. 1993; Nagayama, Shigematsu et al. 2000) and BAI-1 (Nishimori,
Shiratsuchi et al. 1997). An example of anti-metastasis gene activated by p53 is KAI
(Schindl, Birner et al. 2001).
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(5) Cellular senescence: Normal human cells have a finite lifespan, which allows
only certain numbers of DNA replications. This has been defined as the cellular
replicative senescence and it is mainly caused by telomere shortening (Linskens, Harley
et al. 1995). For example, human skin cell chromosomes lose 50-100 nucleotides at the
telomere ends following each DNA replication cycle, due to the intrinsic mechanism built
in the replication procedure of the DNA lagging strand. After certain generations, the
continuous shortening of the DNA leads to intolerable level of DNA loss and causes
genomic instability. As a result, the cells which inherited the unstable chromosomes quit
the cell cycle and enter into a phase called replicative senescence (Levy, Allsopp et al.
1992). In this way, telomere, the repetitive DNA composing the chromosome ends
provides a counting mechanism to prevent the infinite DNA replication and cell
proliferation. It has been suggested that besides apoptosis, cellular senescence is another
mechanism to prevent the cells bearing defective DNA from tumorigenic transformation
(Sager 1991; Yeager, DeVries et al. 1998). Additionally, cellular senescence is also
suggested to be involved in aging.
Senescence can also be induced through telomere-independent pathways. A
variety of stimuli including oncogenic or mitogenic signals, chromatin remodeling, DNA
damage or tumor suppressor activity have all been reported to elicit cellular senescence.
Some tumor suppressors such as p16 (the cyclin-dependent kinase inhibitor) and p14
ARF (the inhibitor of oncogene MDM2) respond to these senescence-inducing stimuli
(McConnell, Starborg et al. 1998; Dimri, Itahana et al. 2000). Although the mechanism
of p53 regulation of senescence remains elusive, there are indications that p53 responds
to senescence-inducing stimuli through ATM and sensitizes the cells in a way similar to
7

DNA damage induced p53 activation (Vaziri 1997; Vaziri, West et al. 1997; Lansdorp
2000). It is very likely that p53 induces p21 expression, which in concert with p16
initiates and sustains the senescence growth arrest of the cells (Atadja, Wong et al. 1995;
Vaziri, West et al. 1997; Stein, Drullinger et al. 1999).

Activation of p53
P53 is usually maintained at low levels in the cells by virtue of its short half-life.
One of the most important functions of p53 in suppressing tumorigenesis is to respond to
cellular stress, achieved by promoting the cell cycle arrest or apoptosis of the DNAdamaged cells by transcriptionally regulating target genes bearing the aforementioned
functions. In this way, given the time by p53 induced cell cycle arrest, the cells
containing damaged DNA are repaired or removed by apoptosis to keep the homeostasis
of the cells. Thus, this DNA-damage response of p53 is crucial for avoiding neoplasia
generated from DNA lesions.
One of the most potent DNA damages inflicted on the cells is DNA double strand
break. This can be elicited from ionizing radiation, certain chemical agents or genotoxic
stress. Ataxia telangiectasia is an autosomal recessive genetic disorder featured by
neurodegeneration, immunodeficiency, radiation sensitivity and cancer predisposition
(Crawford 1998; Becker-Catania and Gatti 2001). On genetic level, ataxia telangiectasia
is caused by the loss or inactivation of ATM protein, which belongs to a conserved
family of proteins, PI3 kinase like protein kinases or PIKK. Most of the PIKK family
proteins possess serine/threonine kinase activity. ATM kinase responds to DNA double
8

strand breaks by phosphorylating proteins crucial to various DNA response pathways
(Banin, Moyal et al. 1998; Canman, Lim et al. 1998).
One of the main targets of ATM kinase is p53, the activation of which mediates
the G1-S cell cycle arrest by inducing the expression of CDK inhibitor p21. Upon DNA
damage, ATM phosphorylates p53 on Serine 15 (Banin, Moyal et al. 1998; Canman, Lim
et al. 1998; Khanna, Keating et al. 1998). Moreover, ATM also phosphorylates and
activates CHK2, a checkpoint kinase that phosphorylates p53 on Serine 20. (Bartek,
Falck et al. 2001; McGowan 2002). Another ATM phosphorylation target is MDM2 at
serine 395, which disrupted the nuclear export signal that is needed for efficient p53
export into the cytoplasm (Maya, Balass et al. 2001). MDM2 affects p53 in both its
function and its stability. In order to keep p53 inactive and at low protein level, MDM2
binds to the N-terminal transactivation domain and inhibits the transcription factor
function of p53. On the other hand, MDM2 is the ubiquitin E3 ligase, mediating the
ubiquitination and degradation of p53 by proteasome. Furthermore, the NES on MDM2
has been reported to enhance MDM2 mediated ubiquitination and degradation of p53.
These aforementioned phosphorylations dissociate p53 from the binding to its major
negative regulator MDM2, thus significantly contributes to the stabilization and
activation of p53 as a transcription factor. Other PIKK family proteins such as ATR and
ATX carry out similar functions in phosphorylating p53 (Hammond, Denko et al. 2002;
Heffernan, Simpson et al. 2002). Even though they can collaborate with ATM in the
double strand break response, ATR and ATX are also activated in response to different
genotoxic stresses, such as UV-irradiation and hypoxia.

9

P53 regulation by MDM2 and MDMX
As a tumor suppressor, p53 functions to inhibit growth and proliferation of abnormal
cells, which impose a potential threat for tumorigenesis. In mouse models, p53 null mice
showed high incidence of tumor formation, supporting p53 as a tumor suppressor
(Donehower, Harvey et al. 1992; Livingstone, White et al. 1992; Yin, Tainsky et al.
1992; Fukasawa, Wiener et al. 1997). The stability and activity of p53 are mostly
regulated by MDM2. MDM2 is one of the down stream targets of p53 and the expression
of MDM2 is often elevated subsequent to p53 activation (Barak, Juven et al. 1993;
Zauberman, Flusberg et al. 1995). As mentioned above, MDM2 possesses E3 ubiquitin
ligase activity towards p53 and acts as a major negative regulator to keep p53 stability
and activity at low level (Oliner, Pietenpol et al. 1993; Zauberman, Barak et al. 1993;
Haupt, Maya et al. 1997; Honda and Yasuda 1999). Thus, the relationship between p53
and MDM2 composes the classic negative feedback loop, whereas the elevation of
MDM2 expression by p53 leads to the down regulation of p53 itself (Wu, Bayle et al.
1993). The importance of MDM2 as the major negative regulator of p53 is also revealed
in mouse models. Nullifying MDM2 leads to embryonic lethality at day 3.5 due to the
massive apoptosis induced by p53, supporting MDM2 as a major p53 negative regulator
(Jones, Roe et al. 1995). Furthermore, the embryonic lethality of MDM2 null mice can
be rescued by crossing into p53 null background, indicating the major role of MDM2 is
to negate p53 functionality. This indicates the intrinsic mechanism in cells to keep p53
level under tight control.
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The negative effect of MDM2 inflicted on p53 is not without control. As the
inhibition of MDM2 favors p53 function, MDM2 inhibitor might possess tumor
suppressor characteristics. ARF is such a tumor suppressor. ARF expression is elevated
upon the induction by certain genetic stress signals such as E1A, E2F, myc, ras and v-abl.
Consequently, as a major negative regulator of MDM2, ARF inhibits MDM2 mediated
p53 ubiquitination and degradation while negating MDM2’s inhibition of p53
transcriptional activity (Kamijo, Weber et al. 1998; Pomerantz, Schreiber-Agus et al.
1998; Stott, Bates et al. 1998; Zhang, Xiong et al. 1998).
The other important p53 regulator is MDMX, an MDM2 homolog. Recently,
MDMX was found as another P53 binding protein besides MDM2 (Shvarts, Steegenga et
al. 1996). MDMX and MDM2 share significant homology in several functional domains,
such as P53 binding domain, Zn finger and the RING domain. MDMX was also found to
be able to inhibit P53 transactivation. However, no feedback loop is formed between p53
and MDMX because MDMX does not contain p53-responsive element on the promoter
and is not induced by p53 activation. On the other hand, MDMX has not been found to
possess ubiquitin E3 ligase activity so it does not directly affect p53 stability (Jackson
and Berberich 2000; Stad, Ramos et al. 2000). Nonetheless, MDMX has been
established as another important negative regulator of p53. The MDMX knockout mice
died at embryonic day 7 due to severe proliferation deficiency in contrast of massive
apoptosis as in the case of MDM2 knockout mice. Similar to MDM2 null mice, this
embryonic lethality can be rescued by nullifying P53 simultaneously (Parant, ChavezReyes et al. 2001; Finch, Donoviel et al. 2002; Migliorini, Denchi et al. 2002). This
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demonstrated the non-overlapping functionality of MDMX with MDM2 in embryonic
development as well as its major function in P53 regulation.

P53 posttranslational modification
P53 responds to DNA damage signals through an increase in transcriptional
activity and protein stability. The accumulation of active p53 largely relies on p53
posttranslational modifications (Appella and Anderson 2001). Compared to the change
in transcriptional or translational rate, posttranslational modification is a time-efficient
way to elevate the activity of p53 as a transcription factor in stress response. So far,
reported posttranslational modifications of p53 include phosphorylation, ubiquitination,
acetylation, neddylation and sumoylatoin, each of them has profound effect on p53
stability and/or activity.
P53 phosphorylation is pivotal for its activation after DNA damage. The Nterminus of p53 is phorsphorylated by at least three different protein kinases, ATM, ATR
and DNA-PK (Banin, Moyal et al. 1998; Canman, Lim et al. 1998; Tibbetts, Brumbaugh
et al. 1999; Nagayama, Shigematsu et al. 2000). The central event in this process is the
phosphorylation of p53 Serine 15 and Serine 37, leading to the dissociation of MDM2
from p53 (Avantaggiati, Ogryzko et al. 1997; Shieh, Ikeda et al. 1997; Lambert,
Kashanchi et al. 1998; Dumaz and Meek 1999; Zhang and Xiong 2001). Alternatively,
MDM2 as the major negative regulator of p53 can also be phorsphorylated, favoring its
dissociation from p53 (Mayo, Turchi et al. 1997). In addition, the C-terminal serine
residue 378 undergoes dephosphorylation upon DNA damage, leading to the recruitment
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of 14-3-3 adaptor protein followed by the enhanced DNA binding affinity of p53
(Waterman, Stavridi et al. 1998).
P53 acetylation also regulates the protein-protein interaction and activity of p53.
It has been suggested that the phosphorylation in p53 N-terminus potentiates the
acetylation by transcriptional co-activators CBP/P300 and PCAF, thus enhancing p53
transcriptional activity and stability (Avantaggiati, Ogryzko et al. 1997; Gu, Shi et al.
1997; Lill, Grossman et al. 1997; Sakaguchi, Herrera et al. 1998; Dumaz and Meek
1999). P53 activity is also under the control of HDACs, which often associate with
transcription co-repressors and remove acetyl groups from substrates (Murphy, Ahn et al.
1999; Juan, Shia et al. 2000). The deacetylation of p53 may represent a mechanism to
help restore cell biological functions when the damage is repaired and hyperactive p53 is
no longer needed. As the major negative regulator of p53, MDM2 blocks p53 acetylation
both in vivo and in vitro, suppressing the tumor suppressor function of p53 (Kobet, Zeng
et al. 2000; Ito, Lai et al. 2001).
P53 stability is most directly regulated by its ubiquitination. Aforementioned
MDM2-mediated ubiquitination sends p53 to 26S proteasome degradation and explains
the particularly short half-life of p53. Besides MDM2, Pirh2 and COP1 are both p53inducible genes and could mediate the ubiquitination and degradation of p53, forming
negative feedback loops (Leng, Lin et al. 2003; Dornan, Wertz et al. 2004). The fact that
multiple proteins converge on the negative regulation of p53 emphasizes the importance
of keeping p53 level under strict control. Alternatively, the mechanism de-ubiquitinating
p53 should hypothetically restore p53 stability. HAUSP is one such antagonist to MDM2
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ubiquitination activity of p53, removing ubiquitin molecules from p53 and increases the
protein half-life (Li, Chen et al. 2002).
Besides ubiquitin, ubiquitin-like small molecules such as Nedd8 or sumo have
also emerged as p53 modifiers that regulate p53 activity (Melchior and Hengst 2002;
Harper 2004; Xirodimas, Saville et al. 2004). Both neddylation and sumoylation utilize
parallel mechanisms to ubiquitination in that the ubiquitin-like molecules need to be
activated and transferred to substrates by E1 and E2 enzymes, respectively. MDM2
promotes conjugation of both sumo and nedd8 to p53. However, p53 sumoylation and
neddylation have opposite effects on its transcription activity whereas sumoylation of p53
moderately enhances its transactivation while MDM2-mediated neddylation of p53
inhibits its function (Melchior and Hengst 2002; Harper 2004; Xirodimas, Saville et al.
2004).

P53 as a cancer therapy target
Cancer is among the top 3 causes of death in United States. To date, the treatment
of cancer still heavily relies on chemotherapies and radiotherapies, which primarily
converge to the functionality and activity of p53. In order to evade from p53 tumor
suppressive functions, about 50% of human tumors have p53 mutated (Hollstein,
Sidransky et al. 1991; Levine, Momand et al. 1991). In the rest of the cases, the
maintenance of wild type p53 accompanies deficiencies of other components in the p53
regulatory pathway, such as the amplification of MDM2 or the loss of function of ARF.
Realizing the pivotal role of p53 in cancer control, scientists have endeavored to
develop p53-targeting therapeutic strategies. They can be categorized into two classes.
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The first tactic targets cancer cells containing mutant p53. This is based on the
hypothesis that the function of mutant p53 can be restored to that of the wild type.
Theoretically, cells bearing mutant p53 not only risk loss of function of the tumor
suppressor, but also obtain the gain of function activity of oncogene as the p53-mutant
allele exhibits dominant negative activity to silence the proper function of the wild type
p53. Strategies were developed to either eliminate cells bearing mutant p53, exemplified
by Onyx-015, or correction of mutant p53 functions, represented by PRIMA-1 (Heise,
Sampson-Johannes et al. 1997; Ries, Brandts et al. 2000; Rogulski, Freytag et al. 2000;
Bykov, Issaeva et al. 2002; Lebedeva, Su et al. 2003; Haupt and Haupt 2004).
The second class aims to boost the activity of wild type p53. In a significant
percentage of tumors, p53 status remains wild type, but accompanied with
overexpression or amplification of MDM2. MDM2 is one major negative regulator for
both p53 stability and activity. To this end, peptide and small molecule inhibitors have
been developed to achieve the abrogation of MDM2-P53 binding, alleviating the
suppression of p53 (Haupt and Haupt 2004).

15

MDM2
MDM2 History
MDM2 or Murine Double Minute Clone 2 was originally cloned from the
abnormal chromosomes called double minute (Cahilly-Snyder, Yang-Feng et al. 1987;
Fakharzadeh, Trusko et al. 1991). These chromosomes frequently harbor amplified genes,
leading to uncontrolled cell proliferation and tumorigenesis. The amplification of MDM2
in mice resulted in high risk of tumor formation, giving scientists the first sign that
MDM2 is an oncogene. Later, MDM2 was co-purified with p53 and found to negatively
regulate p53 stability and transcriptional activity (Momand, Zambetti et al. 1992). Since
p53 has been defined as a tumor suppressor gene, the inactivation of which by MDM2
established MDM2 as an oncogene.

MDM2 mouse model and clinical relevance
One of the crucial experiments established MDM2 as a major regulator of p53
tumor suppressor was done in mouse models. P53 -/- mice were viable but developed
tumors after birth, supporting the role of p53 as a tumor suppressor. MDM2-/- mice were
embryonic lethal, died at embryonic day 3.5. If the lethality of MDM2 null mice is
caused by the loss of MDM2 negative regulation of p53, then crossing p53 to the MDM2
null background should be able to rescue MDM2 null mice from lethality. This was
proven true (Jones, Roe et al. 1995; Montes de Oca Luna, Wagner et al. 1995). Beside,
concerning tumor formation, MDM2 knockout and MDM2/p53 double knockout mice
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are similar. Thus, the mouse model supports the hypothesis that MDM2 is an oncogene
and its essential role is to negatively regulate p53.
If MDM2 is the major inhibitor of the tumor suppressor p53, then p53 loss of
function alone is sufficient for tumorigenesis, precluding the need for amplification of
MDM2 function. Indeed, the mutation of p53 and gene amplification of MDM2 do not
often coincide. MDM2 gene amplification was first detected in a significant number of
osteosarcomas and soft tissue tumors and the research up to date shows a 7% overall
amplification frequency of MDM2 (Momand, Jung et al. 1998). Furthermore, in some of
the tumors that maintain both functional p53 and normal level of MDM2, MDM2 can
still be hyperactive due to the loss of function of another tumor suppressor ARF
(Pomerantz, Schreiber-Agus et al. 1998; Zhang, Xiong et al. 1998). As a major negative
regulator of MDM2, ARF is mutated at high frequency in human cancers (Momand, Jung
et al. 1998).

MDM2 inhibits p53 transcriptional activity
Although p53 can induce apoptosis independent of its transcription activity, P53
tumor suppressor function is largely dependent on its role as a transcription factor. Upon
genotoxic stresses, p53 induces apoptosis, cell cycle arrest, DNA repair and inhibition of
angiogenesis. Some of the genes containing p53 responsive element and induced by p53
include p21, GADD45, 14-3-3 σ, Bax, PUMA, and MDM2 (Kastan, Zhan et al. 1992;
Barak, Juven et al. 1993; Perry and Levine 1993; Perry, Piette et al. 1993; Miyashita,
Krajewski et al. 1994; Chan, Hermeking et al. 1999; Nakano and Vousden 2001).
Distinct from other p53 inducible genes, MDM2 binds to the transcriptional activation
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domain on the N-terminus of p53, inhibiting p53 transcription of its downstream targets,
thus established a negative feedback loop between p53 and MDM2 (Barak, Juven et al.
1993; Juven, Barak et al. 1993; Wu, Bayle et al. 1993; Barak, Gottlieb et al. 1994). This
is necessary for the proper growth and proliferation of the cells under normal condition
because p53 overexpression will lead to cell death or growth arrest. However, upon
DNA damage, rather high level of p53 is needed to harness the growth of damaged cells
and send them either to DNA repair or apoptosis pathway. At this point, the physical
association between MDM2 and p53 is broken by the phosphorylation of p53 at serines
critical for p53/MDM2 binding. Without the inhibition by MDM2, p53 is
transcriptionally active and elicits cell cycle arrest or apoptosis to the damaged cells. In
this sense, the override of p53 by MDM2 allows DNA damaged cells to proliferate,
leading to tumorigenesis.

MDM2 is an ubiquitin E3 ligase for multiple proteins
In the ubiquitination pathway, E3 ubiquitin ligases are the group of enzymes
catalyzing the conjugation of ubiquitin moiety to the protein substrates. To date, there
are two major groups of ubiquitin E3 ligases. One is the HECT domain containing E3,
catalyzing ubiquitin conjugation by forming thio-ester intermediates between E2 and the
substrates. The other class is the RING finger domain ubiquitin E3 ligases, featured by
the consensus sequence CX2CX (9-39)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C. MDM2 is a
RING domain type of E3.
So far, proteins diverse in their functions have been found to be the ubiquitin
ligase substrates of MDM2. These proteins include p53, MDM2 itself, MDMX, b18

arrestin, PCAF and insulin-like growth factor 1 receptor (IGF1R) (Momand, Zambetti et
al. 1992; Fang, Jensen et al. 2000; Shenoy, McDonald et al. 2001; Girnita, Girnita et al.
2003; Pan and Chen 2003; Jin, Zeng et al. 2004). The ubiquitination of these substrates
by MDM2 leads to the rapid turnover of the proteins through proteasome degradation.

MDM2 promotes other posttranslational modifications of p53
Besides being an E3 ligase for p53 and other substrate proteins, MDM2 also
stimulates other forms of posttranslational modifications. Sumo-1 is a 110 amino acid
protein belonging to an ubiquitin-like family. The conjugation of sumo to a variety of
proteins changes protein localization or activity. It was reported that MDM2 mediates
p53 sumoylation, which moderately enhances p53 transcriptional activity (Melchior and
Hengst 2002). Upon DNA damage, p53 is also acetylated by acetyl transferase
CBP/P300. The acetylation of p53 contributes to its stabilization. MDM2 suppresses
p53 acetylation by binding to and inhibiting the function of CBP/P300, rendering p53
more susceptible to degradation (Kobet, Zeng et al. 2000; Ito, Lai et al. 2001).
Furthermore, MDM2 promotes the conjugation of another ubiquitin-like molecule, nedd8
to p53, leading to the transcriptional inhibition of p53 activity (Harper 2004; Xirodimas,
Saville et al. 2004).

MDM2 nuclear import and export
MDM2 contains both nuclear localization signal (NLS) and nuclear export signal
(NES), making it possible for transportation in and out of the nucleus independently
(Roth, Dobbelstein et al. 1998; Tao and Levine 1999). In recent years, MDM2 has been
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reported to mediate the nuclear export of p53 into cytoplasm, rendering p53 more
susceptible for proteasome degradation in the cytoplasm (Roth, Dobbelstein et al. 1998;
Tao and Levine 1999). Experiments using Leptomycin B blocked the nuclear export of
proteins, as a result, p53 was stabilized and its transcriptional activity enhanced
(Freedman and Levine 1998). However, MDM2-independent p53 nuclear export might
also exist (Zhang and Xiong 2001).
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MDMX
MDMX Protein structure
In 1996, a novel p53-binding protein was identified and named MDMX for its
structural similarity with the well-established p53-binding protein, MDM2 (Shvarts,
Steegenga et al. 1996). MDMX shares significant homology with MDM2 in its protein
structure. Compared with MDM2, which is 491 amino acids, MDMX is a 490 amino
acid protein that shares several functional domains with MDM2 (Shvarts, Bazuine et al.
1997). Over the years, it has been recognized that MDMX and MDM2 share highly
conserved domains in three main regions (fig 2). The first region spans amino acid 4294, comprising the p53-binding domain. This domain is strictly conserved between
MDM2 and MDMX, sharing 53.6% identity (Bottger, Bottger et al. 1999).

This

conserved region enables both MDMX and MDM2 to bind p53 on its N-terminal
transactivation domain and inhibit p53 transcription activity. The second conserved
domain or, the Zinc binding domain locates in the central region of both proteins, which
is comprised of residues 301-329. The function of the Zinc finger domain is still largely
enigmatic. The third highly conserved region is in the C-terminus of both proteins,
between amino acid 444-483. This RING finger domain is characterized by its CX2CX (939)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C

consensus sequence (Sharp, Kratowicz et al. 1999;

Tanimura, Ohtsuka et al. 1999). MDMX and MDM2 share 53.2% identity in this region,
which enables the homo- and hetero-dimerization of the two. By using the yeast twohybrid analysis system, Tanimura et al demonstrated that the MDMX-MDM2
heterodimer is more stable than the homodimers of each. The RING finger domain of
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MDM2 is necessary and sufficient for its ubiquitin E3 ligase activity (Momand, Zambetti
et al. 1992).

However, in contrast to MDM2, no E3 ligase activity has been found for

MDMX (Jackson, Lindstrom et al. 2001; Migliorini, Danovi et al. 2002; Linares,
Hengstermann et al. 2003).

Figure2. MDM2 and MDMX share homology in their protein
structures

Among the regions that are distinct between MDMX and MDM2 is the central
acidic domain. The acidic domain of MDM2 provides a binding site for ARF. The
interaction between MDM2 and ARF results in the inhibition of MDM2 E3 ligase
activity and the stabilization of both MDM2 and p53 (Weber, Taylor et al. 1999; Zhang
and Xiong 1999). ARF/MDM2 binding also relocates MDM2 from nucleus to nucleolus,
physically separates MDM2 from p53 (Pomerantz, Schreiber-Agus et al. 1998).
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However, the binding between ARF and MDMX remains controversial (Jackson,
Lindstrom et al. 2001; Wang, Arooz et al. 2001). The research of Kawai et al and
Meulmeester et al shed some light on the functional significance of the central acidic
domain of MDM2. Both groups demonstrated that the central acidic region is
indispensable for MDM2 E3 ligase activity, making it a possible explanation for
MDMX’s lack of ubiquitin E3 ligase function (Kawai, Wiederschain et al. 2003;
Meulmeester, Frenk et al. 2003). Other structural discrepancies between MDM2 and
MDMX include the nuclear localization signal (NLS) and nuclear export signal (NES) in
MDM2, which are not conserved in MDMX (Jackson and Berberich 2000; Migliorini,
Danovi et al. 2002; Migliorini, Denchi et al. 2002).

MDMX gene structure
The homology on protein level between MDMX and MDM2 can be explained by
the conservation of the two genes at genomic level (Parant, Chavez-Reyes et al. 2001).
The exons 4-12 between MDMX and MDM2 are well conserved. The last exon, exon 12
encodes RING finger domains of MDM2 and MDMX, resulting in the well-conserved
RING finger domains on protein level. However, the 5’ ends of the genes are quite
distinct. In contrast to MDM2, no p53-responsive element was found on MDMX
(Shvarts, Steegenga et al. 1996). Consistently, MDM2, but not MDMX is induced upon
the activation of p53 after DNA damage.
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MDMX as an oncogene
In order to evade the genomic surveillance from tumor suppressor p53, tumor
cells selectively mutate or delete p53 gene, escaping from the checkpoint control to
proliferate. Alternatively, members of p53 regulatory pathway are involved for the
advantage of tumorigenesis. As the major negative regulator of p53 function and
stability, MDM2 has been shown to have approximately 7% amplification rate in 28
tumor types (Momand, Jung et al. 1998). Moreover, MDM2 amplification and p53
mutation did not concur in these tumors, implicating that MDM2 overexpression is
sufficient for p53 inactivation and tumor formation. In other cases, wild type p53 is
accompanied by the loss of function of ARF, which is the main inhibitor for MDM2,
leading also to hyperactive MDM2 (Momand, Jung et al. 1998; Pomerantz, SchreiberAgus et al. 1998; Zhang, Xiong et al. 1998).
The mouse models demonstrated that MDMX and MDM2 play non-overlapping
roles in negating p53 function (Parant, Chavez-Reyes et al. 2001; Parant, Reinke et al.
2001; Finch, Donoviel et al. 2002; Migliorini, Denchi et al. 2002). MDMX gene
amplification was found in a subset of malignant gliomas (Riemenschneider, Buschges et
al. 1999). MDMX localizes on chromosome 1q32, which contains frequently amplified
sequences including GAC1, REN and RBBP5 in malignant gliomas. In analogy to
MDM2 amplification, no p53 mutation concurred with MDMX amplification in the
malignant gliomas investigated, suggesting that MDMX overexpression alone is
sufficient for p53 inactivation. Furthermore, no MDM2 amplification was found in the
presence of MDMX amplification, supporting the non-overlapping regulation of MDMX
and MDM2 on p53.
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Aberrations of chromosome 1q frequently occur in cervical and ovarian
carcinoma (Danovi, Meulmeester et al. 2004). MDMX overexpression was found in a
significant number of these cancer cell lines and seems to correlate with the presence of
wild type p53 in those cells. In a comprehensive experiment performed by Danovi et al,
over 500 different human primary tumors were investigated for their MDMX status. It
was found that MDMX is overexpressed at the protein level and correlates with 19% of
breast cancers, 19% of colon cancers and 18% of lung cancers. None of the MDMX
overexpression cell lines contains p53 mutation and only few contain MDM2 gene
amplification. Additionally, in the retrovirus-infected MEFcells, MDMX overexpression
caused the immortalization of MEF without the selective pressure for the loss of p53 or
ARF functions. Furthermore, the transformation of MEF by HRasA12 requires p53 loss of
function, which can be achieved by concomitant overexpression of HRasA12 and MDMX.
These findings argue for an important and non-overlapping role of MDMX with MDM2
in negatively regulating p53 tumor suppressive function and implicate MDMX as a
putative oncogene.

MDMX mouse models
In order to elucidate the functional significance of MDMX in vivo, MDMX
heterozygous mice were generated and crossed for the homozygous MDMX knockout
offspring (Parant, Chavez-Reyes et al. 2001; Parant, Reinke et al. 2001; Finch, Donoviel
et al. 2002; Migliorini, Denchi et al. 2002). Although mice bearing heterozygous
MDMX seemed to develop normally, the MDMX -/- mice were not viable, died at E7.525

8.5 dpc due to lack of cell proliferation and massive apoptosis in central nervous system.
However, when MDMX null allele was crossed into the p53 null background, the
generated MDMX/ p53 double null mice were rescued from the embryonic lethality but
were prone to tumorigenesis. Moreover, the loss of MDMX cannot be compensated by
the expression of MDM2. This evidence strongly argues for the function of MDMX as a
major p53 negative regulator in vivo and that MDMX and MDM2 serve to regulate p53
by distinct mechanisms.

MDMX upon DNA damage
Both MDMX and MDM2 proteins contain a p53-binding domain and inhibit the
growth-suppressive function of p53. However, unlike MDM2, MDMX gene does not
possess p53-responsive element thus cannot be induced in a p53-dependent manner after
DNA damage (Shvarts, Steegenga et al. 1996). Early studies have found that MDMX is
constitutively expressed at both mRNA and protein levels during cell proliferation,
differentiation or after DNA damage (Jackson and Berberich 1999). MDMX lacks the
nuclear localization signal (NLS) and is predominantly cytoplasmic in unstressed cells
whereas both p53 and MDM2 possess functional NLS and localize in nucleus
(Migliorini, Danovi et al. 2002). DNA damage induced p53 or MDM2 facilitates the
nucleus translocation of MDMX by forming heterodimeric or heterotrimeric complexes
with MDMX (Migliorini, Danovi et al. 2002). However, MDMX nuclear entry can also
be independent of either MDM2 or p53, demonstrated by the efficient MDMX nuclear
translocation in p53-/-MDM2-/- mouse embryo fibroblasts after DNA damage (Li, Chen
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et al. 2002). Overexpression of MDMX under cellular stress has been shown to enhance
p53 stability and activity due to the competitive binding between MDMX and MDM2 to
p53. Under stressed conditions, overexpressed MDMX dominates the binding to p53,
allowing a p53 population free of potent MDM2 inhibition, leading to enhanced p53dependent apoptosis (Gu, Kawai et al. 2002; Mancini, Gentiletti et al. 2004). Although
this result reflects a potential positive regulation of p53 by MDMX, the MDMX
overexpression under DNA damage is an artificial effort. Studies in our lab and others
found that MDMX is polyubiquitinated and degraded by proteasome in an MDM2dependent fashion after DNA damage (Kawai, Wiederschain et al. 2003; Pan and Chen
2003). Furthermore, this MDM2-dependent polyubiquitination of MDMX can be
enhanced by ARF (Kawai, Wiederschain et al. 2003; Pan and Chen 2003). ARF was
shown to inhibit MDM2 E3 ligase activity toward p53 and MDM2 polyubiquitination and
degradation, leading to stabilization of both proteins (Kamijo, Weber et al. 1998;
Pomerantz, Schreiber-Agus et al. 1998; Stott, Bates et al. 1998; Zhang, Xiong et al.
1998). Additionally, ARF stimulates p53 growth suppressive function and can inhibit
MDM2 or MDMX mediated p53 suppression (Jackson, Lindstrom et al. 2001). By
stimulating the polyubiquitination of MDMX, ARF presumably enhances p53 functions
by targeting both of its negative regulators namely MDMX and MDM2.

MDMX-MDM2-p53
The negative feedback loop between p53 and MDM2 has been well established.
Explicitly, p53 transcriptionally activates MDM2, which negatively regulates p53 by
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inhibiting its transactivation and destabilizing p53 by mediating its proteasome
degradation (Barak, Juven et al. 1993; Juven, Barak et al. 1993; Wu, Bayle et al. 1993;
Barak, Gottlieb et al. 1994). The mouse models experiments support MDMX as another
major negative regulator of p53 function in vivo besides MDM2 (Parant, Chavez-Reyes
et al. 2001; Finch, Donoviel et al. 2002; Migliorini, Denchi et al. 2002; Parant and
Lozano 2003). Moreover, it is well recognized that MDMX can also bind to the Nterminus transactivation domain of p53, thus inhibiting p53 transcriptional function
(Shvarts, Steegenga et al. 1996; Bottger, Bottger et al. 1999; Stad, Ramos et al. 2000).
We now know that MDMX is another substrate of MDM2 E3 ligase activity (Kawai,
Wiederschain et al. 2003; Pan and Chen 2003). MDMX is polyubiquitinated by MDM2
and degraded in a proteasome-dependent pathway. However, two main questions remain
elusive. (1) How does MDMX regulate MDM2 function and stability? (2) How do
MDMX and MDM2 cooperate to regulate p53 function and stability?
One model proposed that MDMX and MDM2 regulate p53 in a mutually
dependent manner. MDM2 is a very unstable protein due to its intrinsic E3 ligase
activity. MDMX stabilizes MDM2 by inhibiting the ubiquitin E3 ligase function of
MDM2 toward itself. On the other hand, MDM2 recruits MDMX to the nucleus where
MDMX retains a nuclear pool of p53 through direct binding. Since MDM2-p53
interaction leads to re-localization of p53 to cytoplasm, where p53 is efficiently degraded,
MDMX stabilizes p53 by retaining it in the nucleus. Meanwhile, MDMX and MDM2
synergistically inactivate p53 transcriptional activity in the nucleus through direct binding
to p53’s transactivation domain. Therefore, MDMX and MDM2 cooperatively inhibit
p53 transcription activity but antagonize each other in regulating p53 stability. This
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model is supported by a majority of the labs employing overexpression technique
(Jackson and Berberich 2000; Stad, Ramos et al. 2000; Stad, Little et al. 2001). The
other model agrees on the observation that MDMX stabilizes p53 but assumes a distinct
mechanism for the stabilization. It is suggested that MDMX over-expression enhances
p53 stability and even functionality through the competitive binding of MDMX to p53
with MDM2. MDMX overexpression has a squelching effect on p53-MDM2 binding,
resulting in more p53 free from MDM2 association and inhibition (Gu, Kawai et al. 2002;
Mancini, Gentiletti et al. 2004). The third model is supported by in vitro assays, showing
that MDMX stimulates the E3 ligase activity of MDM2, explaining the destabilization of
both p53 and MDM2 at the overexpression of MDMX. All except for one group
excluded the possible E3 function of MDMX (Badciong and Haas 2002).
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ARF

P16INK is a cell cycle checkpoint gene that inhibits cyclin-dependent kinase 4
(Sherr and Roberts 1995; Weinberg 1995). The gene locus of p16INK on chromosome 9
is mutated at high frequency in human tumors (Kamb, Gruis et al. 1994; Nobori, Miura et
al. 1994). Later it was found that the necessity in tumor cells to mutate p16 locus lies in
the fact that this locus encodes a second gene transcribed with an alternative reading
frame, namely ARF (fig 3) (Serrano, Hannon et al. 1993; Quelle, Zindy et al. 1995).
Although ARF is completely unrelated to p16, the mutation of ARF also caused high
frequency of tumor genesis independent of p16, supporting ARF as a tumor suppressor
(Foulkes, Flanders et al. 1997; Ruas and Peters 1998; Sharpless and DePinho 1999).
The mechanism of ARF induced cell cycle arrest is distinct from that of p16INK.
A myriad of genetic stress including E1A, E2F, myc, ras and v-abl induce the expression
of ARF. ARF activates the function of tumor suppressor p53 by harnessing p53 inhibitor,
MDM2 (Kamijo, Weber et al. 1998; Pomerantz, Schreiber-Agus et al. 1998; Stott, Bates
et al. 1998; Zhang, Xiong et al. 1998). ARF plays a major role in inhibiting the negative
regulation of MDM2 on p53 through at least three mechanisms. One relies on the
nucleolus localization signal (NoLS) contained within 85-101 residues on the C-terminal
domain of human ARF, enables ARF nucleolus-localization (Kamijo, Weber et al. 1998;
Pomerantz, Schreiber-Agus et al. 1998; Stott, Bates et al. 1998; Zhang, Xiong et al.
1998). By binding to MDM2 central region, ARF recruits MDM2 into nucleolus, thus
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physically separated MDM2 from p53. The second mechanism involves the abrogation
of MDM2 E3 ligase activity by ARF (Weber, Taylor et al. 1999; Zhang and Xiong 1999).
The third mechanism is supported by the experiments showing that ARF attenuates the
suppression of p53 acetylation by MDM2, contributing to the stabilization of p53 (Ito,
Lai et al. 2001). The end result of both mechanisms is that ARF stabilizes and activates
p53, inducing the transcription of a myriad of p53-dependent genes that function in DNA
repair, apoptosis, cell cycle arrest and anti-angiogenesis.

Figure3. p16 and ARF are two tumor suppressors encoded in the
same gene locus but working by distinct mechanisms
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ARF is not a stereotypical inhibitor of MDM2 and the interplay between the two
proteins is still being explored. Nevertheless, previous studies showed that ARF works
on all aspects of MDM2-mediated posttranslational modification. MDM2 ubiquitination
of the substrates including self-ubiquitination is inhibited by ARF, resulting in the
stabilization of the MDM2 E3 substrates (Kamijo, Weber et al. 1998). In addition, in
response to stress signals, p53 is acetylated by CBP/P300, which increases p53 stability.
MDM2 suppresses p53 acetylation by binding to the acetyl transferase CBP/P300 and
inactivating the enzyme. ARF abrogates MDM2’s suppression on p53 acetylation, thus
restores p53 stability and activity (Ito, Lai et al. 2001). Chen et al also demonstrated that
MDM2 stimulatesc p53 sumoylation (Chen and Chen 2003). However, instead of
antagonizing MDM2’s modification on p53, ARF enhances MDM2-mediated p53
sumoylation. Data from this manuscript demonstrated that ARF stimulates MDM2mediated MDMX ubiquitination and MDM2-independent MDMX sumoylation.
Therefore, ARF is a dynamic regulator of MDM2.

Ubiquitination and proteasome degradation review

Cellular protein degradation is a strictly regulated process, affecting all aspects of
biological functions. One important mechanism for protein degradation is through
ubiquitination-proteasome degradation pathway. Ubiquitin, as its name indicated, is a
widely expressed protein present in most of the tissues and organisms, well conserved
from yeast to human. It is a 76-amino acid small protein that can be conjugated through
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an isopeptide linkage to the lysines in the target protein as a post-translational
modification (Pickart 2001; Weissman 2001). Since its initial discovery, ubiquitination
has been recognized in a wide variety of biological processes, ranging from signal
transduction to endocytosis.
Ubiquitin-mediated proteasome degradation is a stepwise procedure (Haas and
Siepmann 1997). The first step involves ubiquitin-activating enzyme E1 activating
ubiquitin in an ATP-dependent fashion. Then ubiquitin molecule is transferred to E2,
ubiquitin-conjugating enzyme, forming a high-energy thio-ester intermediate of E2ubiquitin. E3 ubiquitin ligase is a group of enzymes mostly responsible for substrate
recognition and specificity. There are two sets of E3s classified by their distinct
functional domains. The HECT domain E3s contain a highly conserved 350 amino acid
region in their carboxyl termini that was first discovered in E6-AP, the ubiquitin E3 that
mediates the ubiquitination and degradation of tumor suppressor p53 by association with
E6 viral oncoprotein. HECT domain E3s form intermediates between E2 and the
substrate proteins while the RING domain containing E3s directly transfer E2 to the
substrate proteins (Haas and Siepmann 1997).
RING finger containing proteins were originally recognized merely for its
potential in protein dimerization. Only until recently was it uncovered as a group of
enzymes playing important roles in ubiquitination pathway. RING proteins share
conserved structure CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CH(4-48)CX2C, the cysteines and
histidines represent the zinc binding sites. Crystal structures of RING finger proteins
indicated that the protein structure of RING domain permits the optimal positioning
between E2 and the substrate, ensuring the transfer of ubiquitin to the target protein.
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RING finger E3s can be divided into two groups: single and multi subunit E3s (Haas and
Siepmann 1997). Single-subunit E3s contain the substrate binding site and the RING
finger catalytic domain on one protein. Some of the well-studied single subunit RING
finger E3s include p53 regulating oncoprotein MDM2; Parkin, the mutation of which
associates with juvenile Parkinson’s disease and c-Cbl, a proto-oncoprotein. Multisubunit E3s have the RING finger-containing subunit and the substrate recognition
subunit separated on distinct proteins. Among them are SCF (Skp1/Cul11/F-box
protein), APC (anaphase promoting complex) and VHL-CBC (Von Hippel–Lindau–
Cul2/elongin B/elongin C complex).
Different numbers of the ubiquitination enzymes involved in each step indicates
that the specificity of activity differs among E1, E2 and E3. While only one E1 has been
identified in yeast, there are at least 13 E2s in yeast and 25 E2s in mammalians
discovered so far. In contrast, the most diversity of the ubiquitination enzymes comes
with E3, the ubiquitin ligase. To date, more than a hundred E3s have been recognized,
implicating their role in substrate selection. In order to achieve strictly regulated protein
degradation, different proteins are recognized by distinct ubiquitin ligases, targeting them
to the ubiquitination system. The substrate specificity is reached by the pool of E3s that
recognize only certain proteins for ubiquitination and in the case of polyubiquitination,
often lead to substrate degradation.
Proteins can be modified by a single ubiquitin conjugated to one or more of its
lysine residues, so called monoubiquitination. While the functional significance of
protein monoubiquitination is still elusive, it has been implicated in the regulation of
biological processes such as endocytosis, lysosomal degradation and chromatin
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remodeling. With the presence of an internal lysine in the ubiquitin protein, a polymer
of ubiquitin could also be constructed through isopeptide bond between the C-terminus of
one ubiquitin and the internal lysine 48 residue of the other (Pickart 1997).
.

When conjugated to a target protein, the ubiquitin chain containing no less than

four ubiquitin polymers is often recognized as a signal for proteasome destruction
(Thrower, Hoffman et al. 2000). The destination of destruction for the polyubiquitinated
proteins is the 26S proteasome. It is composed of two major subunits: one is the 20S core
particle that carries out the proteolytic activity; the other is the 19S regulatory particle,
regulating the functionality of the core particle. Both 20S core particle and 19S
regulatory particles contain multiple subunits. The 20S core is a cylindrical barrelshaped structure composed of four rings stacked upon each other. The two rings on both
ends are called α subunits, which gate the entry of the substrates for degradation.
Without the regulation by the 19S caps, the multiple-ubiquitinated proteins cannot enter
the catalytic core for degradation. The 19S regulatory particle carries out multiple
functions: selecting target, processing substrates and leading the entrance of target
proteins to the catalytic core. Across species and between human and yeast, up to 4070% of sequence identity was found in some of the proteasome subunits, indicating
ubiquitination system as one of the most conserved systems in eurkaryotes.
Although targeting substrate proteins for proteolysis is a key function of
ubiquitination, it is becoming clear that ubiquitination plays much more complicated
roles in myriad of biological processes, including DNA damage response, translation
regulation, kinase regulation and endocytosis. The functional mechanism of these
processes has just started to be appreciated.
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Posttranslational modification by ubiquitin is a reversible process. A group of
thiol protease enzymes namely DUBs tightly control the removal of ubiquitin by
dissembling poly-ubiquitin chains and cleaving ubiquitin off the protein substrates
(Wilkinson 1997). This ensures the recycling of the ubiquitin and prevents the
accumulation of ubiquitin chains at the proteasome, which will cause disordered
proteasome functions. DUBs also add to the layer of ubiquitination regulation by
affecting the steady state level of the ubiquitin-conjugated proteins since the
deubiquitination of the protein can rescue it from destruction by proteasome degradation.

Sumoylation process
Posttranslational modification is an efficient way to modulate protein-protein
interaction, stability, function or localization. Small molecules such as ubiquitin,
phosphate, and acetyl conjugate to specific residues on target proteins and modify their
localization, stability or activity. Among these small molecules participated in protein
posttranslational modifications, the functional significance of sumo is less well
understood. Sumo, or small ubiquitin like molecule, is a 101 amino acid protein that
bears homology with ubiquitin (Boddy, Howe et al. 1996; Matunis, Coutavas et al. 1996;
Okura, Gong et al. 1996; Shen, Pardington-Purtymun et al. 1996; Kamitani, Nguyen et al.
1997; Mahajan, Delphin et al. 1997; Tsytsykova, Tsitsikov et al. 1998). Despite the
limited 18% overall sequence homology, sumo and ubiquitin share very similar threedimensional structure and protein folding. Nevertheless, significant differences were
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found between sumo and ubiquitin on the N-terminus structure as well as the surface
charge of both proteins.
The process of sumoylation parallels that of ubiquitination. Both sumoylation and
ubiquitination are processes of stepwise conjugation of the small molecules to the target
proteins, involving functional specific enzymes in each step. Aos1/Uba2 in yeast or
SAE1/SAE2 in human are E1 activating enzymes, activating the sumo or ubiquitin
molecule; E2 conjugates sumo or ubiquitin to E3 or directly to the substrates. Unlike
multiple E2s for ubiquitination, sumoylation has a unique E2, Ubc9. Both
sumo/ubiquitin activation and conjugation steps are ATP-dependent. In the process of
ubiquitination, hundreds of identified E3 ubiquitin ligases provide the substrate
specificity needed to determine the fate and on many occasions, the degradation of the
target proteins. On the other hand, the E3 ligases for sumoylation process have just
emerged and await further investigation. To date, two classes of sumo E3s have been
discovered. The first class consists only one member, the RanBP2, which is a component
of the nuclear pore complex. The other class includes siz1 and siz2 in the S. cerevisiae as
well as the PIAS family, which was first recognized as co-regulators of the JAK-STAT
pathway.

Sumoylation functions
A consensus sumoylation site has been identified. The presence of consensus
sequence ψKXE, where ψ represents a large hydrophobic amino acid and K stands for
the sumo conjugating lysine residue indicates potential modification by sumo
conjugation. Although the number of identified sumo substrates is limited, they seem to
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play important roles in diverse fields such as maintenance of genomic stability, DNA
repair, gene transcription, signal transduction and nuclear pore function.
In 1999, two labs simultaneously discovered that p53 is sumoylated at lysine 386
and this modification activates p53 transcriptional activity (Gostissa, Hengstermann et al.
1999; Rodriguez, Desterro et al. 1999). The requirement for sumo E3 ligase in p53
sumoylation is controversial. Original findings claimed that p53 in vitro sumoylation
requires only sumo-1, E1 and E2. However, it was later discovered that PIAS directly
binds both p53 and Ubc9 and stimulates p53 sumoylation in vitro (Schmidt and Muller
2002). MDM2 was also proved sumoylated and the process is stimulated by ARF
(Xirodimas, Chisholm et al. 2002). The functional significance of MDM2 sumoylation
remains unclear.
RanGAP1 is a regulator of nuclear pore transportation. Unmodified RanGAP1
localizes in the cytoplasm while sumoylated RanGAP1 relocalizes to the nuclear pore
complex and associates with a nuclear pore complex subunit, RanBP2, facilitating
nuclear import (Matunis, Coutavas et al. 1996). PML, promyelocytic leukemia protein is
another example of sumoylation modifying protein subcellular localization (Sternsdorf,
Jensen et al. 1997; Kamitani, Nguyen et al. 1998; Muller, Matunis et al. 1998). Upon
sumo conjugation, PML relocalizes to the nuclear bodies where it recruits Daxx,
inhibiting Daxx-mediated transcription repression of target genes (Kim, Park et al. 2003).
Sumoylation can also regulate transcription by recruiting coactivators or
corepressors to sumo-modified transcription factors. For example, the sumoylation of the
transcription coactivator p300 leads to the recruitment of HDAC6, the histone
deacetylase (Girdwood, Bumpass et al. 2003).
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Various proteins participating in the maintenance of genomic stability are
posttranslational modified by sumo. These include topoisomerase I and II, thymine-DNA
glycosylase enzyme (TDG) as well as the proliferating cell nuclear antigen (PCNA)
(Mao, Desai et al. 2000; Mao, Sun et al. 2000; Saitoh and Hinchey 2000; Hardeland,
Steinacher et al. 2002; Stelter and Ulrich 2003). Sumo modification affects their proteinprotein interaction, subcellular localization or activity.
There are cross talks between sumoylation, ubiquitination, phosphorylation and
acetylation. For example, the phosphorylation of NF-kB stimulates its ubiquitination
while antagonizing sumo conjugation (Huang, Wuerzberger-Davis et al. 2003).
Noticeably, all acetylation, ubiquitination and sumoylation take place solely on lysine
residues. However, modifications on common lysine residues have had both antagonistic
and synergistic functions on certain substrates.
We identified MDMX as another substrate of sumo conjugation. Similar to
MDM2, the sumoylation of MDMX can also be stimulated by ARF. Unlike MDM2
however, MDMX is sumoylated in an ARF independent fashion. In vitro assay revealed
that the presence of sumo-1, E1 and E2 are sufficient for MDMX sumoylation. Major
sumoylation sites of MDMX were identified to two lysines. However, the sumoylation
status of MDMX does not affect its association or function with either p53 or MDM2.
Thus, the physiological significance of MDMX sumoylation remains elusive.

Sumoylation is a reversible process
Sumoylation process is dynamic and reversible. Sumo-specific proteases
participate in both the process of sumo maturation and the cleavage of sumo from the
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substrates. Sumo is synthesized as precursors and processed at the carboxy-terminus
before entering the cycle of sumo activation and conjugation by sumo-specific proteases.
In yeast, the Ulp proteases are crucial for viability. The Ulp homologs in mammalian
cells are a family of enzymes termed SENP (Sentrin-specific protease). To date, four
SENP family members have been characterized (Gong, Millas et al. 2000; Kim, Baek et
al. 2000; Nishida, Tanaka et al. 2000; Nishida, Kaneko et al. 2001). Even though the
substrate specificity of different SENPs are not known, the fact that these SENP family
members distribute in different subcellular compartments indicates that there might be
functional specificity of these sumo proteases. SENP1 localizes in nuceloplasm and
nuclear bodies; SENP2 is concentrated at nuclear pore; SENP3 is contained in nucleolus
and SENP6 resides in cytoplasm (Gong, Millas et al. 2000; Kim, Baek et al. 2000;
Nishida, Tanaka et al. 2000; Nishida, Kaneko et al. 2001; Bailey and O'Hare 2002; Hang
and Dasso 2002). .
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Materials and Methods

Cell Lines

MDM2/p53 double-null mouse embryo fibroblast 174.1 is a kind gift from Dr.
Guillermina Lozano (McMasters, Montes de Oca Luna et al. 1996). ARF/p53 doublenull mouse embryo fibroblast is a kind gift from Dr. Gerry Zambetti. All cell lines
including H1299 (non-small cell lung carcinoma, p53-null), U2OS (osteosarcoma, p53
wild type, ARF-deficient), HFF (passage 20 human primary foreskin fibroblast) and
MCF7 (breast cancer, p53 wild type) cells were maintained in DMEM medium with 10%
fetal bovine serum and 100 units/ml penicillin and streptomycin as well as 1% nonessential amino acids (cellgro).

Plasmids and Reagents

Human MDMX cDNA (myc-MDMX, MDMX-myc-His6) were kindly provided by Dr.
Donna George (Sharp, Kratowicz et al. 1999). The myc epitope tag fused to the MDMX
cDNA was removed by subcloning to generate a non-tagged MDMX. A Flag epitope tag
was added to the C terminus of myc-MDMX by PCR to create double-tagged mycMDMX-Flag. His6-ubiquitin expression plasmid was kindly provided by Dr. David Lane
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(Xirodimas, Chisholm et al. 2002). ARF deletion mutants were kind gifts from Dr. Yue
Xiong (Zhang and Xiong 1999). MDM2 deletion mutants were described previously (Chen,
Marechal et al. 1993; Zhang and Xiong 1999). MDMX deletion mutants were generated by
PCR and subcloned into pcDNA3.1 (+) vector. Point mutants of MDM2 and MDMX were
created using the Quick Change kit (Stratagene). All p53, MDM2, MDMX and ARF
constructs used in this study were of human origin. Monoclonal antibody 8C6 against
human MDMX was generated in our laboratory and reacts specifically with MDMX in a
region between residues 101-393 (Li, Chen et al. 2002). Adenovirus expressing human ARF
was kindly provided by Dr. Yue Xiong and used as described previously (Lu, Lin et al.
2002). U2OS stable cell line expressing tetracycline-repressible human MDM2 was
created by cloning MDM2 cDNA into the pUHD15.1 vector and cotransfecting with
pUHG10.3 (Gossen and Bujard 1992).

Western Blot

Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl,
0.5% NP40, 1 mM PMSF], centrifuged for 5 mins at 10,000 g, and the insoluble debris
were discarded. Cell lysate (10-50 µg protein) was fractionated by SDS-PAGE and
transferred to Immobilon P filters (Millipore) using a semi-dry electro-blotting apparatus
for 1 hr. The filter was blocked for 1 hr with washing buffer containing phosphatebuffered saline (PBS), 5% non-fat dry milk and 0.1 % Tween-20. The filter was then
incubated for 2 hrs with primary antibodies diluted in washing buffer. MDM2 was
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detected by 3G9 with 1:40 dilution (Chen, Marechal et al. 1993); p53 was detected by DO-1
with 1:10,000 dilution (Pharmingen); ARF was detected by 14PO2 (Neomarkers) with
1:2000 dilution and MDMX was detected by 8C6 with 1:40 dilution. The filter was then
washed four times (5 min each) with PBS containing 0.1 % Tween-20. Next, bound
primary antibodies were conjugated with secondary antibody IgG goat-anti-mouse HRP
by incubating the filter with the secondary antibody for two hrs in the washing buffer
containing phosphate-buffered saline (PBS), 5% non-fat dry milk and 0.1 % Tween-20.
The filter was washed and developed using ECL-plus reagent (Amersham).

Immunoprecipitation

Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl,
0.5% NP40, 1 mM PMSF], centrifuged for 5 mins at 10,000 g, and the insoluble debris
were discarded. To detect the binding between MDM2 and MDMX, two mg of total
cellular protein was immunoprecipitated using 100 µl of anti-MDM2 monoclonal
antibody 3G9 and 20 µl packed protein A-Sepharose beads (Sigma) for 3 hours at 4oC.
The beads were then spinned down and washed three times with lysis buffer, boiled in
SDS sample buffer and the immunoprecipitate was fractionated by SDS PAGE followed
by western blot.
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Transfection

Calcium phosphate transfection was performed in H1299 and U2OS cells for their high
transfection efficiency. In transient transfection, 2x106 cells were seeded into 10 cm
tissue culture dishes for 24 hrs. For each transfection, a total amount of 40µg of plasmid
DNA was mixed with 450µl of H2O, 125 mM calcium chloride and 500 µl HEPES (0.28
M NaCl, 0.05 M HEPES, 1.5mM CaCl2). Immediately after mixing, the mixture was
added to the cells and incubated for 16 hours. Transfected cells were washed 5 times
with PBS, refed with complete medium and incubated for another 24 hours before
harvest. In a stable transfection, 48 hours after transfection, the cells were drug selected
by complete medium containing 750 µg/ml G418 for two weeks. Drug-resistant colonies
were either pooled or cloned.
Lipofectamine transfection was performed in MEF cells for their low transfection
efficiency with calcium phosphate transfection (invitrogene). 2x105 cells were seeded
into 6 cm tissue culture dishes for 24 hrs, washed with 3 ml and refed with 2 ml of serumfree medium. For each transfection, a total amount of 4µg of plasmid DNA was mixed
with 250 µl of serum-free medium and 10 µl of lipofectamine plus reagent and incubated
for 15 min at room temperature. Pre-mix 10 µl of lipofectamine with 250 µl serum-free
medium and mix with the DNA solution. The mixture was incubated for another 15 min
before added to the cells. After 3 hrs incubation, the cells were refed with complete
medium.
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Immunofluoresence Staining

Approximately 50,000 cells were plated on chamber slides and incubated for 18 hours
before staining. The cells were fixed by 1:1 ratio acetone/methanol for 3 minutes at RT.
The slides were immediately rinsed two times with washing buffer (PBS with 0.1%
Triton-X 100) and then incubated in washing buffer twice for 5 minutes each. The slides
were blocked with blocking buffer (10% normal goat serum in PBS) for 20 minutes.
Primary antibody 8C6 is diluted 1:40 in the blocking buffer and incubated with the cells
for 2 hrs at RT. Then the slides were rinsed and incubated in washing buffer twice for 5
minutes each. The secondary antibody goat anti-mouse FITC was diluted 1:400 in
blocking buffer and incubated with the cells in dark for 2 hrs. The slides were then
washed and mounted.

In vivo Ubiquitination Assay

H1299 and U2OS cells in 9 cm plates were transfected with combinations of 1 µg GFP
expression plasmid, 5 µg His6-ubiquitin expression plasmid, 1-5 µg human MDMX, 5 µg
MDM2 and 5 µg ARF expression plasmids using conventional calcium phosphate
precipitation method. Thirty-two hours after transfection, cells from each plate were
collected into two aliquots. One aliquot (10%) was used for conventional western blot to
confirm expression and degradation of transfected proteins. The remaining cells (90%)
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were used for purification of His6-tagged proteins by Ni2+-NTA beads. The cell pellet
was lysed in buffer A (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M TrisCl pH8.0, 5 mM imidazole, 10 mM β-mecaptoethanol) and incubated with Ni2+-NTA
beads (Qiagen) for 4 hours at room temperature. The beads were washed with buffer A, B
(8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 M Tris-Cl pH8.0, 10 mM β-mecaptoethanol), C
(8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 M Tris-Cl pH6.3, 10 mM β-mecaptoethanol),
and bound proteins were eluted with buffer D (200 mM imidazole, 0.15 M Tris-Cl pH6.7,
30% glycerol, 0.72M β-mercaptoethanol, 5% SDS). The eluted proteins were analyzed
by western blot for the presence of conjugated MDMX by 8C6 antibody.

In vitro Ubiquitination Assay

GST-MDM2 full-length and deletion mutants were expressed in E. coli and purified by
binding to glutathione-agarose beads. The substrate MDMX was produced by in vitro
translation in rabbit reticulocyte lysate using the TNT system (Promega) in the presence
of 35S-methionine. 15 µl packed beads loaded with ~2 µg GST fusion proteins were
incubated with 4 µl of MDMX in vitro translation product, 250 ng GST-Ubc5Hb (Boston
Biochem), 250 ng purified rabbit E1 (AG Scientific), 2 µg His6-ubiquitin (AG
Scientific), and 20 µl reaction buffer (50 mM Tris pH7.5, 2.5 mM MgCl2, 15 mM KCl, 1
mM DTT, 0.01% Triton X-100, 1% glycerol, 4 mM ATP). The mixture was incubated at
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37˚C for 1 hr with shaking, boiled in SDS sample buffer and fractionated by SDS-PAGE.
The gel was dried and MDMX was detected by autoradiography.
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MDM2 Promotes Ubiquitination and Degradation of MDMX

Abstract

The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and
degradation. Mitogenic signals activate p53 by induction of ARF expression, which
inhibits p53 ubiquitination by MDM2. Recent studies showed that the MDM2 homolog
MDMX is also an important regulator of p53. We present evidence that MDM2 promotes
MDMX ubiquitination and degradation by the proteasomes. This effect is stimulated by
ARF and correlates with the ability of ARF to bind MDM2. Promotion of MDM2mediated MDMX ubiquitination requires the N-terminal domain of ARF, which normally
inhibits MDM2 ubiquitination of p53. An intact RING domain of MDM2 is also
required, both to interact with MDMX and to provide E3 ligase function. Increase of
MDM2 and ARF levels by DNA damage, recombinant ARF adenovirus infection, or
inducible MDM2 expression leads to proteasome-mediated down-regulation of MDMX
levels. Therefore, MDMX and MDM2 are coordinately regulated by stress signals. The
ARF tumor suppressor differentially regulates the ability of MDM2 to promote p53 and
MDMX ubiquitination and activates p53 by targeting both members of the MDM2
family.
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Results

MDM2 stimulates MDMX ubiquitination and degradation

MDM2 is rapidly degraded by the proteasome due to self-ubiquitination (Fang,
Jensen et al. 2000). In contrast, little is known about the regulation of MDMX turnover.
We tested whether it is subjected to ubiquitination in vivo. To detect MDMX
ubiquitination, we coexpressed MDMX and His6-ubiquitin by transient transfection into
H1299 cells. MDMX conjugated to His6-ubiquitin was purified by Ni2+-NTA beads
under denaturing conditions and detected by western blot with MDMX-specific
monoclonal antibody 8C6 (Li, Chen et al. 2002). The result showed that a small portion
of MDMX was conjugated to ubiquitin in vivo (mainly mono-ubiquitination based on
slightly slower mobility than unmodified MDMX). Transfection of MDM2 strongly
stimulated MDMX poly-ubiquitination (Figure 4).
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Figure4. MDM2 stimulates MDMX polyubiquitination. MDMX was
coexpressed with His6 -ubiquitin in H1299 cells by transient transfection.
His6-ubiquitinated proteins were purified, and MDMX was detected by
Western blotting with 8C6 antibody.

Interestingly, cotransfection of MDM2 and ARF did not inhibit but rather stimulated
MDMX polyubiquitination (Figure 5). MDM2 expression level was also increased in the
presence of ARF (due to stabilization) and may account for the increase in MDMX
ubiquitination.
Direct western blot also showed that MDMX expression level was significantly
reduced when coexpressed with MDM2 (Figure 5), suggesting that ubiquitination of
MDMX led to subsequent degradation by the proteasomes.
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Figure 5. MDM2 and ARF synergistically stimulate the polyubiquitination
and degradation of MDMX. MDMX was coexpressed with His6 -ubiquitin in
H1299 cells by transient transfection. His6 -ubiquitinated proteins were purified,
and MDMX was detected by Western blotting with 8C6 antibody (top panel).
The lower panels are control Western blots of nonpurified cell lysate (10% of the
amount used for Ni-NTA purification).
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Consistent with this hypothesis, treatment with proteasome inhibitor MG132 for 4 hours
before cell harvest partially prevented MDMX down-regulation by MDM2 cotransfection
(Figure 6). In the absence of cotransfected MDM2, MDMX was relatively stable and did
not accumulate in the presence of MG132.

Figure 6. MDM2 stimulates MDMX degradation by proteasome pathway.
H1299 cells transfected with the indicated plasmids were treated with 30 µM
MG132 for 4 hours prior to Western blot analysis for MDMX. Transfection
efficiency was verified by expression of cotransfected GFP plasmid.
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To determine whether MDM2 and ARF are required for the basal ubiquitination of
MDMX, the assay was repeated using MDM2/p53-null or ARF/p53-null mouse
fibroblasts. The results showed that mono-ubiquitination of MDMX occurred in the
absence of endogenous MDM2 (Figure 7) and ARF (data not shown). Therefore, MDMX
can undergo ARF and MDM2-independent mono-ubiquitination. Cotransfection of
MDM2 or MDM2 and ARF also stimulated MDMX poly-ubiquitination in mouse cells.

Figure 7. MDMX can be ubiquitinated independent of MDM2. MDM2/p53null 174.1 cells were transfected with the indicated plasmids. Ni-NTA-purified
ubiquitinated MDMX and cell lysate were run on the same gel to show the
molecular weight shift due to MDM2-independent monoubiquitination.
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MDM2 RING domain is sufficient for promoting MDMX ubiquitination

Next, a panel of MDM2 mutants was tested for ubiquitination of MDMX. The
results showed that the RING domain of MDM2 was important for promoting MDMX
ubiquitination (representative mutants are shown in Figure 8 & 10). MDM2 deletion
mutants without the p53-binding or ARF-binding domains were still capable of
stimulating MDMX ubiquitination, indicating that these regions were not essential for
this function. An MDM2 NLS point mutant (182R) that prevents nuclear translocation
was also able to ubiquitinate and degrade MDMX. Furthermore, the C terminal 130
amino acid of MDM2 containing the RING domain was sufficient to ubiquitinate MDMX
(Figure 8 & 10). Deletion of MDMX C terminal RING domain (∆394-490) also
prevented poly-ubiquitination by MDM2 (Figure 9 & 10). Therefore, these results
showed that poly-ubiquitination of MDMX by MDM2 required formation of MDMXMDM2 complex through RING domain-mediated heterodimerization and possibly the E3
function of MDM2.
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Figure 8. MDM2 RING domain is required for stimulating MDMX
polyubiquitination. H1299 cells were transfected with His6 -ubiquitin, MDMX,
and representative MDM2 mutants. MDMX ubiquitination and degradation were
detected by Ni-NTA purification and Western blotting.
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Figure 9. MDMX RING domain is required for its polyubiquitination and
degradation by MDM2. H1299 cells were transfected with His6 -ubiquitin,
MDM2, and MDMX mutants. MDMX ubiquitination was detected by Ni-NTA
purification and Western blotting.
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Figure 10. Diagram of MDM2 and MDMX mutants and summary of results.
MDMX±N has a deletion of residues 1 to 100. MDMX±C has a deletion of residues 394
to 490.
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Ubiquitination of MDMX requires MDM2 ubiquitin ligase function
1

To test whether the E3 function of MDM2 is required for poly-ubiquitination of
MDMX, we mutated three key cysteine and histidine residues in the RING domain of
MDM2 that a previous study found to be important for E3 function (438C-L, 457H-S,
478C-S, Figure 11 & 12) (Fang, Jensen et al. 2000). These mutations prevented polyubiquitination of MDMX in the presence of ARF (Figure 11 & 12).
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Figure 11. Ubiquitination of MDMX requires MDM2 E3 function.
(Upper panel) Position of point mutations in the MDM2 RING domain. C and H
residues important for zinc coordination are underlined.
(Lower panel) Ubiquitination of MDMX by MDM2 mutants was determined by
transfection of H1299 cells.
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When analyzed by MDM2 immunoprecipitation and MDMX western blot, the 438L and
478S mutants lost most or all of MDMX binding, indicating that these mutations affected
both E3 and MDMX binding functions (Figure 12). The 457S mutant was still capable of
binding to MDMX, but the efficiency was significantly lower than wild type MDM2
considering the higher expression levels of both proteins in the transfected cells due to
lack of degradation (Figure 12). Since the absolute amount of 457S-MDMX complex was
comparable to MDM2-MDMX, yet MDMX ubiquitination was much weaker in the
457S-MDMX combination, we concluded that the E3 function of MDM2 was critical for
ubiquitination of MDMX. However, it was clear from these results that MDMX-binding
and E3 functions were both dependent on the integrity of MDM2 RING domain and
could not be completely separated by these mutations.
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Figure 12. Binding of MDMX to MDM2 point mutants. MDMX and MDM2
mutants were cotransfected into H1299 cells and analyzed by MDM2
immunoprecipitation followed by MDMX Western blotting.
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ARF N terminal domain is required to cooperate with MDM2

It is well established that ARF is an inhibitor of MDM2 E3 ligase function on p53
(Zhang and Xiong 2001). The results in Figure 5 showed that its effect on MDM2mediated MDMX ubiquitination was opposite to that of p53. Therefore, we analyzed a
panel of ARF deletion mutants to identify the domain required for stimulating MDMX
ubiquitination. The results showed that the N terminal domain of ARF containing the
MDM2-binding region was required for stimulating MDMX ubiquitination in the
presence of MDM2 (Figure 13). Deleting the nucleolar targeting signal between 82-101
did not prevent stimulation of MDMX ubiquitination (Zhang and Xiong 1999).
Interestingly, the N terminal region of ARF contains the MDM2 binding site and is
sufficient to inhibit p53 ubiquitination by MDM2 (Midgley, Desterro et al. 2000).
Therefore, ARF binding to MDM2 differentially regulates its ability to ubiquitinate p53
and MDMX.
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Figure 13. The ARF N-terminal domain is sufficient to cooperate with
MDM2. (Upper panel) H1299 cells were transfected with MDMX, a suboptimal
amount of MDM2, and different ARF mutants. His6 -ubiquitin-conjugated
MDMX was purified and detected by Western blotting.
(Lower panel) Diagram of ARF mutants and summary of results.
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Although ARF stimulated MDMX ubiquitination, MDM2 alone was sufficient to
induce significant degradation of MDMX even in ARF-deficient cells (data not shown),
indicating that ARF is not essential for this process. To observe stimulation of MDMX
degradation by ARF in H1299 cells requires careful titration to limit the amount of
MDM2 plasmid (data not shown). The effect of ARF on MDMX degradation was more
evident and reproducible in mouse cells (Figure 7), suggesting that cell type may affect
the effect of ARF in this transfection assay.

Regulation of endogenous MDMX level by ARF and MDM2

To determine whether endogenous MDMX expression level was regulated by
ARF, ARF-deficient U2OS cells were infected with ARF adenovirus to restore ARF
expression. As expected, expression of ARF resulted in strong induction of p53 and
MDM2 levels. This was accompanied by reduction of MDMX expression (Figure 14).
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Figure 14. Overexpression of ARF down regulates MDMX level. U2OS cells
were infected with ARF adenovirus at the indicated multiplicity for 24 hours and
analyzed for MDMX, MDM2, and p53 expression levels by direct Western
blotting.
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In the second experiment, primary human foreskin fibroblasts (HFF) were treated
with ionizing radiation to induce MDM2 expression. DNA damage resulted in induction
of p53 and MDM2 expression levels in HFF and corresponding reduction of MDMX
expression (Figure 15). Reduction of MDMX level was also observed after induction of
MDM2 expression by irradiation of U2OS cells, or induction of MDM2 by activating a
temperature-sensitive p53 mutant in H1299 cells (data not shown).

Figure 15. DNA damage induces MDMX degradation. HFF cells were treated
with 10 Gy of gamma radiation for 6 hours and 10 hours, respectively before
collection. The levels of MDMX, MDM2, p53, ARF and actin were determined by
Western blotting.
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To determine whether reduced MDMX level was due to degradation by the
proteasomes, irradiated HFF cells were treated with MG132 for 4 hours prior to analysis.
The decrease in MDMX level after irradiation was blocked by MG132 (Figure 16),
suggesting it was mediated by proteasomes. In contrast, the p53-null H1299 cells did not
express elevated MDM2 after irradiation and MDMX level was not reduced.

Figure 16. Induction of MDM2 results in MDMX degradation by proteasomes. HFFs and H1299 cells were treated with 10 Gy of gamma radiation for
6 hours. MG132 (30 µM) was added immediately after radiation. The MDMX
level was determined by Western blotting.
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To determine if the reduction of MDMX protein level after DNA damage is
caused by the change in MDMX mRNA level, we performed Northen blot. The analysis
using several cell lines confirmed that MDMX mRNA level was not reduced by radiation
(Figure 17). These results suggested that ionizing radiation induced proteasome-mediated
degradation of MDMX, which may be due to p53 activation and induction of MDM2
expression.

Figure 17. Gamma irradiation does not reduce the MDMX mRNA level.
Cells were treated with gamma radiation, and 6 hours later total RNA was isolated
and hybridized with an MDMX cDNA probe in a Northern blotting analysis.
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To test whether change in MDM2 level independent of p53 activation or radiation
was sufficient to regulate MDMX level, we created a U2OS cell line expressing
tetracycline-repressible MDM2. Induction of MDM2 expression by removal of
tetracycline correlated with decrease of MDMX level (Figure 18, lanes 5 and 7), which
was restored by a 4 hour MG132 treatment. Therefore, increase of MDM2 expression
alone was sufficient to promote MDMX degradation. However, the moderate decrease of
MDMX was not proportional to the strong induction of MDM2, suggesting that other
factors may limit the efficiency of MDMX degradation by MDM2.
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Figure18. Induction of MDM2 correlates with MDMX degradation through
proteasome pathway. U2OS cells stably expressing tetracycline-repressible
MDM2 were cultured in the presence or absence of 0.5 µg of tetracycline/ml for
20 hours. MG132 was added for the last 4 hours. MDMX and MDM2 levels were
determined by Western blotting.

Epitope tagging prevents MDMX degradation by MDM2

Previous studies using epitope-tagged MDMX did not indicate an effect of MDM2 on
MDMX degradation (Sharp, Kratowicz et al. 1999; Jackson, Lindstrom et al. 2001). We
also had inconsistent results in early experiments when tagged and non-tagged versions
of MDMX were used interchangeably. A direct comparison of non-tagged MDMX with
several versions of epitope tagged MDMX revealed that addition of c-myc or Flag
epitopes to the C terminus of MDMX significantly inhibited poly-ubiquitination by
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MDM2 and completely prevented degradation (Figure 19). Therefore addition of epitopes
to the RING domain of MDMX interferes with ubiquitination and degradation by
MDM2. Because of this finding, all of the results described above were from repeat
experiments using the non-tagged version of MDMX.

Figure 19. MDMX degradation is inhibited by C-terminal epitope tags.
(A) H1299 cells were transfected with MDMX with different epitope tags at the
N or C terminus and subjected to Ni-NTA purifi-cation and Western blotting.
The MDMX-myc-His6 protein was com-pletely recovered by Ni-NTA beads as
expected.
(B) Diagrams of epitope-tagged MDMX and summary of results. C-terminal
epitope tags block polyubiquitination and degradation by MDM2.
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MDM2 promotes MDMX poly-ubiquitination in vitro

In order to confirm the role of MDM2 as an E3 for the poly-ubiquitination of
MDMX, we established an in vitro ubiquitination assay for MDMX. In this assay, GSTMDM2 was able to stimulate the poly-ubiquitination of in vitro translated MDMX in the
presence of purified E1 and E2 (GST-UbcH5b) (Figure 20). Furthermore, the C terminal
fragment of MDM2 containing the RING domain was sufficient to promote MDMX
ubiquitination, whereas an MDM2 N-terminal fragment had no effect. These results
corroborate the in vivo ubiquitination results of Figure 8 and demonstrate that MDM2
functions as an ubiquitin E3 ligase for MDMX.
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Figure 20. MDM2 promotes MDMX polyubiquitination in vitro. GST-MDM2,
GST-RING (containing MDM2 residues 290 to 491), and GST-N (containing MDM2
residues 1 to 150) were purified using glutathione agarose beads. Loaded beads were
incubated with in vitro-translated MDMX in the presence or absence of E1 and E2 in
an ubiquitination reaction as described in Materials and Methods. Poly-ubiquitinated
MDMX appears as a high-molecular-weight smear above the unmodified MDMX
band.
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Discussion

The results described above show that MDMX is subjected to modification by
ubiquitin conjugation. Interaction with MDM2 leads to strong stimulation of MDMX
poly-ubiquitination and degradation by proteasomes. MDM2 appears to function as an
ubiquitin E3 ligase in this process, since the MDM2457S RING domain mutant that
prevents p53 or self-ubiquitination also abrogates ubiquitination of MDMX while still
partially retaining MDMX binding. Furthermore, purified recombinant GST-MDM2 is
able to stimulate MDMX poly-ubiquitination in cell-free conditions. MDMX also
undergoes basal mono-ubiquitination independent of MDM2, suggesting interaction with
other ubiquitination factors. It is noteworthy that previous studies using epitope-tagged
MDMX did not observe an effect of MDM2 on MDMX degradation (Sharp, Kratowicz et
al. 1999; Jackson, Lindstrom et al. 2001).We found that MDMX tagged with c-myc or
FLAG epitopes at the C terminus were resistant to ubiquitination and degradation by
MDM2, possibly due to altered RING domain conformation. Therefore, use of nontagged or N terminally tagged MDMX appears to be critical for detecting its efficient
ubiquitination and degradation by MDM2.
Surprisingly, ARF stimulates MDMX ubiquitination by MDM2, which is
opposite to its effect on p53 ubiquitination. The stimulating effect of ARF is carried out
by the N terminal domain that normally inhibits MDM2 ubiquitination of p53. Therefore,
ARF interaction with MDM2 differentially affects its E3 function toward different
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substrates rather than inactivating its E3 function in general. This effect is plausible
because ARF does not directly interact with the RING domain of MDM2, which may be
involved in recruiting E2. Binding of ARF to the acidic domain of MDM2 may simply
alter its ability to properly orient E2 for the transfer of ubiquitin to certain substrates. In
the case of p53, ubiquitin conjugation is blocked. However, in the case of MDMX,
ubiquitination is not affected or even stimulated. ARF increases MDM2 expression level
by stabilization, which may account for increased MDMX ubiquitination. However, ARF
may also qualitatively stimulate the E3 activity of MDM2 toward MDMX.
These results suggest that ARF is a more effective and multi-functional regulator
of the p53 pathway than previously appreciated. By blocking the ability of MDM2 to
ubiquitinate p53, ARF is sufficient to induce p53 stabilization and activation.
Additionally, by increasing MDMX ubiquitination, ARF also simultaneously promotes
the elimination of another important inhibitor of p53. The combination of these two
functions should result in more potent activation of p53. Because p53 activation induces
MDM2 expression, higher MDM2 level should further cooperate with ARF to degrade
MDMX, resulting in a positive feedback effect. Activation of p53 by other stress signals
such as DNA damage also leads to strong induction of MDM2 expression. Increased
MDM2 level may in fact facilitate p53 activation by degrading MDMX, while its own
interaction with p53 is temporarily blocked by phosphorylation (Figure 14, 15 & 16).
The MDM2 negative feedback loop is an important mechanism in p53 regulation.
However, knock out experiments showed that MDMX is also critical for regulating p53
(Parant, Chavez-Reyes et al. 2001; Finch, Donoviel et al. 2002; Migliorini, Denchi et al.
2002). Recent studies suggested that MDMX and MDM2 depend on each other for
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efficient inhibition of p53. MDM2 stimulates MDMX by targeting it to the nucleus,
whereas MDMX enhances MDM2’s ability to degrade p53 in a highly dose-dependent
manner (Gu, Kawai et al. 2002; Migliorini, Danovi et al. 2002). Therefore, MDMX may
be part of a more complicated MDM2 feedback loop by regulating MDM2 function and
acting as a receiver of other signals. The ability of MDM2 to degrade MDMX ensures
that it also exists in a balance with MDM2 and p53. Although MDMX can inhibit p53
function, the dependence on a suicidal interaction with MDM2 enables MDMX to be
regulated by other signals. The MDMX degradation mechanism also ensures that stress
signals can efficiently activate p53 by coordinately regulating both p53 inhibitors (Figure
21).
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Figure 21. MDMX is regulated by stress signals. MDM2 and MDMX
cooperate to inhibit p53 activity in the absence of stress. Stress signals
activate p53 by targeting both MDM2 and MDMX. Oncogenes such as E2F1
and c-myc induce ARF expression, which activates p53 by inhibiting p53
ubiquitination and promoting MDMX ubiquitination by MDM2. DNA
damage activates p53 and induces MDM2 expression, which in turn degrades
MDMX and leads to further activation of p53. DNA damage also promotes
MDMX nuclear translocation, which may expose it to degradation by
MDM2 but also enables it to inhibit p53 more efficiently at certain stages of
the damage response.

Recent studies showed that ectopically expressed MDMX is mainly localized in
the cytoplasm and undergoes nuclear translocation by both MDM2-dependent and –
independent mechanisms (Gu, Kawai et al. 2002; Li, Chen et al. 2002; Migliorini, Danovi
et al. 2002). Nuclear entry of MDMX is critical for its ability to inhibit p53 (Gu, Kawai
et al. 2002; Migliorini, Danovi et al. 2002), suggesting that MDMX plays an active role
in limiting p53 activation during DNA damage response. However, results presented in
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this report show that DNA damage can induce degradation of MDMX, which would
facilitate p53 activation. Therefore, the net outcome of these regulatory events on the
function of MDMX may depend on the level of damage and different stages of the stress
response. Further work will be required to elucidate the role of MDMX in p53 regulation
during DNA damage and other stress conditions.
In summary, our findings reveal that MDMX expression level is directly regulated
by MDM2-mediated ubiquitination. The results also identify ARF as a more dynamic
regulator of MDM2 ubiquitin ligase function and suggest a potential mechanism of
MDMX regulation by a variety of stress signals through MDM2 and ARF. Elucidating
how MDMX ubiquitination and degradation is regulated should lead to better
understanding of its role in the p53 pathway and tumorigenesis.
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MDMX forms trimeric complex with MDM2 and ARF

Abstract
ARF is a tumor suppressor that functions mainly through inhibition of MDM2,
which is the major negative regulator of p53. ARF directly binds to MDM2 and inhibits
its E3 ubiquitin ligase activity toward p53 and MDM2 itself, thus stabilizes both proteins.
Furthermore, ARF relocates MDM2 from nucleus to nucleolus, physically separates
MDM2 from p53 and activates p53 transcriptional activity. Previous studies showed that
ARF stimulates p53 and MDM2 sumoylation. Our studies in this manuscript
demonstrated that ARF stimulates both ubiquitination and sumoylation of MDMX while
the ubiquitination of MDMX led to its degradation in an MDM2-dependent fashion. In
this study, we showed that ARF stimulates MDMX ubiquitination while stabilizing
MDM2, which may account for the stimulation of MDMX ubiquitination by ARF.

On

the other hand, the binding between MDMX and ARF has been controversial. Here we
demonstrated that MDMX binds to ARF in an MDM2-dependent fashion. Our previous
data showed that ARF N-terminus stimulates MDMX ubiquitination and sumoylation.
We found that ARF N terminus is also required for binding to MDMX in the presence of
exogenous or endogenous MDM2.
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Introduction

Retinoblastoma protein (Rb) and p53 are two tumor suppressors that have been
found to exhibit loss of function in large percentage of human tumors. The main function
of Rb lies in its regulation of E2Fs, which promote cell cycle progression (Weinberg
1995; Dyson 1998). Oncogenic signals such as Ras, induce the phosphorylation of Rb
through cyclinD-Cdks and free E2F from the sequestration of Rb, promoting entry into S
phase (Sherr 2001). In this pathway, there is another tumor suppressor working in the
upstream of this Rb-E2F pathway: p16INK4a is a Cdk inhibitor that inhibits cyclindependent kinase 4 and disrupts the cyclin-Cdk complexes, thus maintaining Rb in the
hypophosphorylated and active state in inhibiting the cell cycle progression promoted by
E2Fs (Sherr and Roberts 1995; Weinberg 1995; Sherr 2001). The gene locus of p16INK
on chromosome 9 is mutated at high frequency in human tumors (Kamb, Gruis et al.
1994; Nobori, Miura et al. 1994). Later it was found that the necessity in tumor cells to
mutate p16 locus lies in the fact that this locus encodes a second gene transcribed with an
alternative reading frame, namely ARF (Serrano, Hannon et al. 1993; Quelle, Zindy et al.
1995).
Although ARF is completely unrelated to p16, the mutation of ARF also caused
high frequency of tumor genesis independent of p16, supporting ARF as a tumor
suppressor (Foulkes, Flanders et al. 1997; Ruas and Peters 1998; Sharpless and DePinho
1999). The mechanism of ARF induced cell cycle arrest is distinct from that of p16INK.
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A myriad of genetic stress including E1A, E2F, myc, ras and v-abl induce the expression
of ARF, which activates the function of tumor suppressor p53 by harnessing p53
inhibitor, MDM2 (Kamijo, Weber et al. 1998; Pomerantz, Schreiber-Agus et al. 1998;
Stott, Bates et al. 1998; Zhang, Xiong et al. 1998).
Thus, ARF plays an important role in linking the Rb-E2F with p53-MDM2 signal
transduction pathways. When mitogenic signal induced E2F activity reaches a critical
threshold, ARF is induced and activates another checkpoint protein: p53, which executes
cell cycle arrest or apoptosis.

Figure 22. ARF connects Rb-E2F pathways to p53-MDM2
pathway
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Results

MDMX forms trimeric complex with MDM2 and ARF

It is well recognized that ARF binds to MDM2 in the acidic domain and inhibits
MDM2’s regulation of p53. However, the binding between MDMX and ARF has been
controversial. In order to compare the binding efficiency between MDMX-ARF to that
of MDM2-ARF, FLAG-tagged MDMX or FLAG-tagged MDM2 were cotransfected with
myc-tagged ARF in H1299 cells. The FLAG-tagged proteins were immunoprecipitated
by M2 beads and co-precipitated ARF protein was detected by Western blot using
monoclonal antibody 14P02 against ARF (Fig 23). The result showed that ARF binds to
MDM2. MDMX overexpression does not change the binding efficiency between MDM2
and ARF. No significant MDMX-ARF binding was detected in the absence of
overexpressed MDM2. However, in the presence of overexpressed non-tagged MDM2,
significant amount of ARF was pulled down by FLAG-MDMX, indicating that MDM2
mediated the binding between MDMX and ARF. MDM2 lacking the RING domain,
which is the MDMX binding region, did not mediate the binding between FLAG-MDMX
and ARF; neither did the two MDM2 mutants lacking ARF binding regions. This
experiment suggests that MDM2 bridges the binding between MDMX and ARF and that
a tertiary complex can be formed among MDM2, MDMX and ARF.
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Figure 23. MDMX forms trimeric complex with MDM2 and ARF. FLAGMDMX and FLAG-MDM2 were cotransfected with ARF expression plasmids in
H1299 cells in the presence or absence of non-tagged MDMX or MDM2
mutants. FLAG-MDMX or FLAG-MDM2 was immunoprecipitated by M2
beads followed by western blot against FLAG-tagged proteins with rabbit-antiFLAG antibody to show the level of immunoprecipitated MDMX and MDM2
(top panel). Co-immunoprecipitated ARF was detected by Western blot using
mouse monoclonal antibody 14P02 against ARF (2nd panel). Expression level of
MDM2 was confirmed by western blot with rabbit-anti-MDM2 antibody (3rd
panel). The level of ARF expressed was verified by direct western blot against
ARF in the whole cell lysate (4th panel). Transfection efficiency was verified by
expression of cotransfected GFP plasmid (bottom panel).
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To further confirm the binding between MDMX and ARF, the experiment was
repeated in H1299 cells with FLAG-p53 as another positive control. FLAG-MDMX and
MDM2 were cotransfected in the presence or absence of overexpressed ARF. Previous
studies showed that ARF binds directly to both MDM2 and p53 (Kamijo, Weber et al.
1998). Indeed, we observed that ARF was co-precipitated with either FLAG-p53 or
FLAG-MDM2. However, significant ARF-MDMX binding was only detected when
MDM2 was coexpressed, verifying MDM2’s recruitment of ARF to MDMX (Fig 24).
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Figure 24. MDM2 enhances the binding between MDMX and ARF. FLAGp53, FLAG-MDMX and FLAG-MDM2were cotransfected in the presence or
absence of ARF in H1299 cells. FLAG-tagged proteins were
immunoprecipitated by M2 beads followed by western blot against FLAGtagged proteins with rabbit-a-FLAG antibody to show the level of
immunoprecipitated p53, MDMX and MDM2 (top panel). Coimmunoprecipitated ARF was detected by Western blot using mouse monoclonal
antibody against ARF (2nd panel). Transfection efficiency was verified by
expression of cotransfected GFP plasmid (3rd panel). The level of ARF expressed
was verified by direct western blot against ARF in the whole cell lysate (3rd
panel)
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MDM2 mediates the binding between MDMX and ARF

In order to verify the binding between MDMX and ARF, we used UO2S cells,
which lacks endogenous ARF expression. MDMX was cotransfected with myc-tagged
wild type ARF and ARF deletion mutants. Immunoprecipitation was performed using
protein A beads and mouse monoclonal antibody against myc-tag. Co-precipitated
MDMX was detected in western blot by rabbit polyclonal antibody against MDMX. The
result showed that MDMX was co-precipitated with wild type as well as the N-terminal
mutants of ARF. ARF C terminus cannot bind to MDMX. ARF98Q is mutated at the
NoLS sequence and retains the capability to bind MDMX (Fig 25). To see if MDMXARF binding is cell-type specific, we performed the experiment in H1299 cells and
observed similar result (data not shown). We speculated that the binding is mediated by
endogenous MDM2 in both cell lines. To find out if MDM2 is required for MDMX-ARF
binding, we performed the same experiment in MEF 174.1, which is a p53/-/MDM2-/cell line that lacks endogenous MDM2. Result showed that only in the presence of
MDM2 does MDMX bind to ARF, indicating that the previously observed MDMX and
ARF binding in U2OS and H1299 cells was possibly mediated by endogenous MDM2 in
those cell lines (Fig 25). Thus, MDM2 bridges the binding between MDMX and ARF
and the MDM2-binding region in ARF N-terminus is required for the indirect binding
between MDMX and ARF.
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U2OS

174.1(p53-/- MDM2-/-)

Figure 25. ARF N-terminus is required for binding MDMX. MDMX was
cotransfected with myc-tagged wild type ARF or ARF deletion mutants as well
as ARF nucleolus localization-deficient mutant into U2OS and MEF174.1(p53-/MDM2-/-), respectively. Myc-ARF was immunoprecipitated by protein A beads
and anti-myc-tag antibody. Co-precipitated MDMX was detected by western
blot using rabbit polyclonal antibody against MDMX. The MDMX expression
level was shown by western blot against MDMX using mouse monoclonal
antibody 8C6 against MDMX from the whole cell lysate. Transfection
efficiency was verified by expression of cotransfected GFP plasmid.
87

ARF does not affect the binding efficiency between MDM2 and MDMX
Since we observed that MDM2 enhanced the binding between MDMX and ARF
(Fig 23-25), we speculated that the tertiary complex formation results in the increased
binding affinity among the three proteins. To find out if MDMX and MDM2 binding
efficiency can be changed by overexpression of ARF, H1299 cells were transiently
transfected with fixed amount of MDMX and increasing amount of MDM2 and ARF.
MDMX was immunoprecipitated with mouse monoclonal antibody 8C6 and the coprecipitated MDM2 was detected by rabbit polyclonal antibody against MDM2. The
result showed that the expression of ARF did not affect the binding efficiency between
MDMX and MDM2 (Fig 26).
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Figure 26. ARF does not affect the binding efficiency between MDM2 and
MDMX. MDMX was cotransfected with increasing amount of MDM2 and ARF
and was immunoprecipitated by protein A beads and mouse anti-MDMX
antibody 8C6. Co-precipitated MDM2 was detected by western blot using rabbit
polyclonal antibody against MDM2 (top panel). The MDMX and ARF
expression levels were shown by western blot from the whole cell lysate (middle
panels). Transfection efficiency was verified by expression of cotransfected
GFP plasmid (bottom panel).
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ARF stimulates MDM2-mediated MDMX ubiquitination by stabilizing MDM2
Previously, we showed that MDM2 promotes the ubiquitination and degradation of
MDMX; additionally, ARF enhances ubiquitination of MDMX by MDM2. However, it
remains unclear whether ARF stimulates MDMX ubiquitination through stabilizing
MDM2 or through other unknown mechanisms. To find out if ARF can stimulate
MDMX ubiquitination without stabilizing MDM2, we performed the ubiquitination assay
by titrating the amount of MDM2 and ARF. H1299 cells were transiently transfected
with suboptimal amount of MDM2 and increasing amount of ARF in the presence of
MDMX and his6-ubiquitin. The result showed that MDMX ubiquitination is enhanced
with increasing amount of ARF but in accordance with increasing amount of MDM2
stabilized by ARF overexpression (Fig 27). In concert with the finding that MDM2
mediates the binding between MDMX and ARF, our data suggests that ARF stimulates
MDM2-mediated MDMX ubiquitination most likely by enhancing the steady state level
of MDM2, which directly ubiquitinates MDMX.
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Figure 27. ARF stimulates MDMX ubiquitination while stabilizing MDM2.
(Upper panel) H1299 cells were transfected with MDMX, suboptimal amounts of
MDM2, and increasing amount of ARF. His6-ubiquitin-conjugated MDMX was
purified and detected by Western blotting. (lower panels) The levels of MDM2,
MDMX, ARF were detected by western blot from cell lysate. GFP level indicates
transfection efficiency.
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Discussion

ARF directly binds p53 and MDM2 and regulates their functions (Kamijo, Weber
et al. 1998). However, the binding between MDMX and ARF has been controversial
with one group showing no binding (Wang, Arooz et al. 2001) and the other group
showed the otherwise (Jackson, Lindstrom et al. 2001). In this study, we confirmed the
binding between MDMX and ARF in vivo, which is mediated by MDM2. However, the
tertiary complex composed of MDMX, MDM2 and ARF failed in enhancing the binding
affinity between MDMX and MDM2. This may be accounted for by the tight complex of
the heterodimer between MDMX and MDM2 and the binding of which do not need
further augmentation.
ARF is not a stereotyped regulator on MDM2 and the interplay between the two
proteins is still being explored. Nevertheless, previous studies showed that ARF works
on all aspects of MDM2-mediated posttranslational modifications. MDM2 ubiquitination
of the substrates including self-ubiquitination is inhibited by ARF, resulting in the
stabilization of the MDM2 E3 substrates (Kamijo, Weber et al. 1998). In addition, in
response to stress signals, p53 is acetylated by CBP/P300, which increases p53 stability.
MDM2 suppresses p53 acetylation by binding to the acetyl transferase CBP/P300 and
inactivating the enzymes. ARF abrogates MDM2’s suppression on p53 acetylation, thus
restores p53 stability and activity (Ito, Lai et al. 2001). Chen et al also demonstrated that
MDM2 stimulates p53 sumoylation (Chen and Chen 2003). However, instead of
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antagonizing MDM2’s modification on p53, ARF enhances MDM2-mediated p53
sumoylation. Data from this manuscript demonstrated that ARF stimulates MDM2mediated MDMX ubiquitination and MDM2-independent MDMX sumoylation.
Therefore, ARF is a dynamic regulator of MDM2 and the relationship between p53,
MDM2, MDMX and ARF awaits further exploration.
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Modification of MDMX by Sumoylation

Abstract
MDMX is a homolog of MDM2 and is critical for regulating p53 function during mouse
embryonic development. MDMX level is regulated by MDM2-mediated polyubiquitination, which results in accelerated degradation after DNA damage or expression
of ARF. In this report, we demonstrated that MDMX can be modified by conjugation to
SUMO-1 both in vivo and in vitro. We found that double mutation of two lysine residues;
K254 and K379 abrogated MDMX sumoylation in vivo. Experiments using the
sumoylation-deficient MDMX mutant showed that it undergoes normal ubiquitination
and degradation by MDM2, normal nuclear translocation and degradation after DNA
damage, and inhibits p53 with wild type efficiency. Therefore, sumoylation is not
required for several activities of MDMX under our assay conditions.
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Introduction

The p53 pathway is regulated by multiple mechanisms, which is critical for its
ability to respond to stress and suppress tumor formation. P53 turnover is regulated by
MDM2, which functions as an ubiquitin E3 ligase to promote p53 ubiquitination and
degradation by the proteasome. Stress signals such as DNA damage induce p53
accumulation by phosphorylation of p53 and MDM2 (Prives and Hall 1999). Mitogenic
signals activate p53 by induction of the ARF tumor suppressor encoded by an alternative
open reading frame in the p16INK4a locus, which inhibits the E3 ligase function of
MDM2 (Kamijo, Weber et al. 1998; Zhang and Xiong 2001). MDM2 also regulates the
acetylation of p53 by preventing binding of p300/CBP or recruitment of HDAC1 (Kobet,
Zeng et al. 2000; Ito, Lai et al. 2001; Ito, Kawaguchi et al. 2002).
Recent studies revealed that p53 is also regulated by the MDM2 homolog MDMX
(Shvarts, Steegenga et al. 1996). MDMX shares strong homology to MDM2 at the amino
acid sequence level and can bind to p53 and inhibit its transcription function in transient
transfection assays. MDMX alone does not promote p53 ubiquitination or degradation in
vivo (Stad, Little et al. 2001). However, formation of MDM2-MDMX heterodimer
stimulates the ubiquitin E3 ligase activity of MDM2 for itself and p53 (Badciong and
Haas 2002; Linares, Hengstermann et al. 2003), suggesting that MDMX may function as
a regulator or cofactor of MDM2. Knockout of MDM2 in mice results in embryonic
lethality due to hyper-activation of p53 (Montes de Oca Luna, Wagner et al. 1995).
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Several studies showed that MDMX-null mice also die in uterus in a p53-dependent
fashion, which can be rescued by crossing into the p53-null background (Parant, ChavezReyes et al. 2001; Finch, Donoviel et al. 2002; Migliorini, Denchi et al. 2002). Therefore,
MDMX is also an important regulator of p53 during embryonic development. MDMX
overexpression can lead to transformation in cell culture; MDMX gene amplification and
overexpression has been observed in certain tumors with wild type p53, suggesting that it
may contribute to p53 inactivation in cancer (Ramos, Stad et al. 2001; Danovi,
Meulmeester et al. 2004).
Recently, p53 and MDM2 have been found to be modified by SUMO-1
conjugation (Small ubiquitin-like modifier) (Gostissa, Hengstermann et al. 1999;
Rodriguez, Desterro et al. 1999; Xirodimas, Chisholm et al. 2002). Sumoylation of p53
and MDM2 in vitro are carried out by a universal SUMO activating E1 enzyme
(SEA1/SEA2 heterodimer) and SUMO conjugating enzyme E2 (ubc9) (Hochstrasser
2002). SUMO is activated in an ATP-dependent manner by E1, transferred to E2, and
subsequently attached to the ε-amino group of lysines on target proteins (Hochstrasser
2002). The sumoylated lysine residue in many substrates often locates within a consensus
sequence of ψKxE where ψ is an aliphatic residue (Rodriguez, Dargemont et al. 2001).
Lysine 386 is the major sumoylation site for p53 (Gostissa, Hengstermann et al. 1999;
Rodriguez, Desterro et al. 1999), whereas the sumoylation site on MDM2 has not been
positively identified (Xirodimas, Chisholm et al. 2002; Chen and Chen 2003).
The functional role of sumoylation is diverse among different substrates. It has
been proposed to be important for regulating the localization, activity, and degradation of
target proteins (Hochstrasser 2002). Initial studies using p53 386 lysine-to-arginine
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mutant resistant to sumoylation suggested that sumoylation moderately enhances p53
transcription activity (Gostissa, Hengstermann et al. 1999; Rodriguez, Desterro et al.
1999). Muller et al. found that the p53 386K mutant has slightly impaired apoptotic
activity (Muller, Berger et al. 2000). Other studies did not observe such an effect (Minty,
Dumont et al. 2000; Kwek, Derry et al. 2001), possibly due to different assay conditions.
MDM2 sumoylation has been shown to be stimulated by ARF through nucleolar targeting
of MDM2 (Xirodimas, Chisholm et al. 2002; Chen and Chen 2003). MDM2 and ARF
cooperatively stimulate p53 sumoylation (Chen and Chen 2003), suggesting a potential
mechanism that contributes to ARF activation of p53. Despite efforts by several
laboratories, the sumoylation site on MDM2 has not been determined, possible due to
presence of multiple alternative sites. The lack of sumoylation-deficient MDM2 mutants
prevents further investigation of the functional of this modification.
Recent work from several laboratories showed that MDMX is regulated by
MDM2-mediated ubiquitination and degradation (Kawai, Wiederschain et al. 2003;
Linares, Hengstermann et al. 2003; Pan and Chen 2003). Ubiquitination of MDMX leads
to increased degradation after DNA damage and expression of ARF (Kawai,
Wiederschain et al. 2003; Pan and Chen 2003), suggesting that ubiquitination is an
important modification on MDMX. In this report, we present evidence that similar to p53
and MDM2, MDMX is also modified by sumoylation. Two lysine residues critical for
MDMX sumoylation have been identified. MDMX point mutants that cannot be modified
by sumoylation have similar properties as wild type MDMX in several functional assays,
suggesting that sumoylation are not required for these MDMX functions.
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Results

MDMX is posttranslationally modified by sumo-1

MDM2 has been demonstrated to be modified by sumo-1. Since MDMX and
MDM2 share significant sequence homology, we speculated that MDMX might also be
sumoylated in vivo. To detect MDMX sumoylation, we coexpressed MDMX and His6sumo-1 by transient transfection into H1299 cells. MDMX conjugated to His6-sumo-1
was purified by Ni2+-NTA beads under denaturing conditions and detected by western
blot with MDMX-specific monoclonal antibody 8C6. The result showed that
coexpression of MDMX and his6-sumo-1 resulted in the appearance of MDMX species
at 90 kd molecular weight, suggesting that MDMX was sumoylated in vivo (Figure 28).
Expression of the desumoylating enzyme SENP1 completely eliminated the 90 kd
MDMX band (Gong, Millas et al. 2000), consistent with it being a sumoylated form of
MDMX.
It has been demonstrated that the sumoylation of MDM2 can be significantly
enhanced by ARF (Xirodimas, Chisholm et al. 2002; Chen and Chen 2003). To test if
ARF also stimulates the sumoylation of MDMX, ARF was cotransfected together with
MDMX and His6-sumo-1. In analogy to MDM2 sumoylation, MDMX sumoylation was
also enhanced by the overexpression of ARF (Figure 28). The significance and
mechanism of this effect remains to be determined.
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Figure 28. ARF stimulates MDMX sumoylation and the sumo-specific
protease SENP1 desumoylates MDMX.
MDMX was coexpressed with His6 -sumo in H1299 cells by transient
transfection. His6-sumoylated proteins were purified, and MDMX was detected by
Western blotting with 8C6 antibody.
The lower panels are control Western blots of nonpurified cell lysate (10% of the
amount used for Ni-NTA purification).Transfection efficiency was verified by
expression of cotransfected GFP plasmid.

99

We have recently reported that MDM2 functions as an E3 ligase for MDMX
polyubiquitination (Pan and Chen 2003). Furthermore, MDM2 expression also stimulates
p53 sumoylation (Chen and Chen 2003). Therefore, we tested whether MDM2 and p53
regulate MDMX sumoylation. The results showed that expression of MDM2 led to
degradation of MDMX in a RING finger-dependent fashion as expected. The level of
MDMX sumoylation was also reduced accordingly, suggesting that MDM2 does not
stimulate MDMX sumoylation (Figure 28). Coexpression of wild type p53 significantly
reduced transfection efficiency and MDMX expression level due to squelching effects,
the corresponding reduction of sumoylated MDMX level also ruled out a stimulatory
effect.
Next, we tested whether MDMX sumoylation can be recapitulated in cell-free
conditions. In vitro translated MDMX was incubated with Hela cell E1 fraction, purified
E2, and ATP. Significant modification of MDMX was observed after addition of
purified sumo-1 (Figure 29). Addition of in vitro translated ARF had no effect on
MDMX sumoylation level in this assay, possibly due to insufficient amount and poor
binding to MDMX under the assay condition, or that the in vivo stimulatory effect
involved additional factors.
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Figure 29. In vitro sumoylation of MDMX.
In vitro translated proteins were incubated in the presence or absence of E1 fraction,
E2, ATP or SUMO1. ARF did not stimulate MDMX sumoylation in vitro.

Identification of MDMX sumoylation sites

The consensus sequence for sumoylation has been identified as ψKXE, where ψ
represents a large hydrophobic amino acid and K stands for the sumo conjugating lysine
residue. However, despite the presence of such consensus site, previous studies were not
able to definitively identify the sumoylation site on MDM2 (Xirodimas, Chisholm et al.
2002; Chen and Chen 2003). To determine the region containing sumoylation sites on
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MDMX, a panel of MDMX deletion mutants was generated with N or C terminal
truncations (Figure 30). The MDMX deletion mutants were coexpressed with His6sumo-1 by transient transfection into H1299 cells, purified by Ni2+-NTA beads under
denaturing conditions and detected by western blot with MDMX polyclonal antibody.
The result showed that major sumoylation sites are contained within the region 250-490
(Figure 31).
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Figure 30. The major sumoylation sites of MDMX are contained within the
region 250-490.
A panel of MDMX deletion mutants was generated for their sumoylation status.
MDMX deletion mutants were coexpressed with His6 -sumo in H1299 cells by
transient transfection. His6-sumoylated proteins were purified, and MDMX deletion
mutants were detected by Western blotting with polyclonal rabbit-anti-MDMX
antibody.
The lower panels are control Western blots of nonpurified cell lysate, showing the
expression of the MDMX deletion mutants (10% of the amount used for Ni-NTA
purification).
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Figure 31. Diagram of MDMX mutants and summary of results.
Major MDMX sumoylation sites are contained within the region 250-490.

The MDMX sequence contains three sites that conform to the ψKXE consensus,
lysine 254 (IKVE), 379 (IKKE) and 478 (CKKE). To directly test whether these sites are
required for sumoylation, single or combined site-directed mutagenesis of these three
lysines were performed. The mutants were tested for their sumoylation efficiency by
transient transfection of H1299 cells. MDMX sumoylation was not affected by the
mutation of any single lysines. However, double-mutation of K254 and K379 to arginine
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abrogated the sumoylation of MDMX (Figure 32). Therefore, K254 and K379 are likely
to be the major sumoylation sites, which is consistent with the deletion mutant results.

Figure 32. Characterization of MDMX sumoylation sites on serine 254 and
serine 379.
Point mutants serine 254, 379 and 478 were generated for identification of
MDMX sumoylation sites. Sumoylated wild-type MDMX and MDMX point
mutants K254, K379, K478 and the double mutant of K254 and K379 (DM) as
well as the triple mutant of all three serines in the consensus sequence were
purified by Ni-NTA purification and detected by Western blot with 8C6 antibody.
The lower panels are control Western blots of nonpurified cell lysate (10% of the
amount used for Ni-NTA purification).
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SENP1 has been identified as a sumo-specific protease. In order to further verify
the modification of MDMX by sumo, we cotransfected His6-sumo-1 with wild type
MDMX, MDMX sumo-deficient single mutants, double mutant and triple mutant in
H1299 cells in the presence or absence of SENP1 expression plasmid. Sumoylated
MDMX was purified by Ni2+-NTA purification and detected by Western blot. The result
showed that SENP1 reversed the sumoylation of wild type MDMX and all three MDMX
point mutants but had no effect on sumoylation-deficient MDMX double or triple
mutants, confirming the characterization of MDMX sumoylation sites (Figure 33).
.
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Figure 33. Desumoylation of MDMX by SENP1.
H1299 cells were transfected with His6-SUMO1 and indicated plasmids.
Sumoylated MDMX was detected by Ni-NTA purification and Western blot.
Expression of SENP1 abrogated MDMX sumoylation.

MDMX sumoylation does not affect its stability and regulation by DNA damage

MDMX forms a heterodimer with MDM2 and is poly-ubiquitinated and degraded
by MDM2. MDMX is also modified by mono-ubiquitination in the absence of MDM2
expression through unknown mechanism (Pan and Chen 2003). To test if blocking
MDMX sumoylation affects its ubiquitination, we coexpressed MDMX and His6107

ubiquitin by transient transfection into H1299 cells. MDMX conjugated to His6-ub was
purified by Ni2+-NTA beads under denaturing conditions and detected by western blot
with MDMX-specific monoclonal antibody 8C6. The result showed that K254 and K379
single or double mutations had little effect on MDMX mono-ubiquitination (Figure 34).
Interestingly, mutating K478 led to significantly higher mono-ubiquitination either alone
or in the triple mutant background. Since K478 is located immediately after the last
cysteine residue of the RING finger, its mutation to arginine may have stimulated the
weak self-ubiquitination of MDMX (Badciong and Haas 2002). Poly-ubiquitination of
the MDMX mutants by MDM2 was similar to wild type MDMX (Figure 34), suggesting
that lack of sumoylation does not affect MDMX ubiquitination by MDM2. Surprisingly,
the K478R mutant was also poly-ubiquitinated and degraded at similar efficiency
compared to wild type MDMX, suggesting that increased basal mono-ubiquitination does
not promote poly-ubiquitination and degradation by MDM2.

108

Figure 34. Lack of sumoylation does not affect MDMX monoubiquitination or polyubiquitination by MDM2.
MDMX and His6-ubiquitin were coexpresssed by transient transfection into
H1299 cells. MDMX conjugated to His6-ub was purified by Ni2+-NTA beads
under denaturing conditions and detected by western blot with MDMXspecific monoclonal antibody 8C6.
MDMX sumoylation status has little effect on the stability of MDMX. The
lower panels are control Western blots of non-purified cell lysate (10% of the
amount used for Ni-NTA purification). Transfection efficiency was verified
by expression of cotransfected GFP plasmid.

Next, the MDMX sumo-deficient double point mutants were cotransfected with
increasing amount of MDM2 in H1299 cells. To further compare the sensitivity of
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MDMX sumoylation mutants to MDM2-mediated degradation, a titration experiment was
performed with fixed amount of MDMX plasmid and increasing amount of MDM2
plasmid in the transfection. The dose-dependent degradation by MDM2 was also similar
between wild type and mutant MDMX, suggesting that MDMX sumoylation status does
not directly affect its stability regulated by MDM2 (Figure 35).

Figure 35. MDMX sumoylation status does not affect its MDM2-mediated
degradation.
MDMX and MDMX sumoylation-deficient double mutant were cotransfected with
increasing amount of MDM2. The level of MDMX was detected by Western blot
with 8C6 antibody.

Previous studies showed that MDMX is destabilized upon DNA damage in an
MDM2-dependent fashion (Kawai, Wiederschain et al. 2003; Pan and Chen 2003).
Recent work in our lab suggested that DNA damage-induced phosphorylation of MDMX
might play a role in accelerating MDMX degradation (manuscript in preparation). To
test if blocking MDMX sumoylation affects its regulation by DNA damage, U2OS cells
were stably transfected with control vector, wild type MDMX and MDMX sumo110

deficient mutants. Cells were treated with ionizing radiation and collected at different
time points. We found that both wild type and sumo-deficient MDMX were degraded at
similar efficiency after DNA damage (Figure 36).

Figure 36. MDMX sumoylation status does not affect its DNA damage induced
destabilization.
U2OS cells were stably transfected with control vector, wild type MDMX and
MDMX sumo-deficient mutants. Cells were treated with ionizing radiation and
collected at different time points. The levels of MDMX, MDM2, p53, p21 and actin
were detected by Western blot.

111

MDMX is mainly localized in the cytoplasm of cells when expressed at high
levels and undergoes nuclear translocation after DNA damage through both MDM2mediated and MDM2-independent mechanisms (Li, Chen et al. 2002)
. When compared to wild type MDMX, the sumoylation-deficient MDMX
mutants also translocated into the nucleus after ionizing radiation (Figure 37). Therefore,
we conclude that sumoylation is not required for the regulation of MDMX localization
and stability after DNA damage.

Figure 37. Sumoylation-deficient MDMX mutants translocated into the
nucleus after ionizing radiation in the same fashion as wild type MDMX.
MDMX mutants were transfected in H1299 cells and r irradiated. Cells were
incubated for 18 hrs before collection. MDMX was detected by 8C6 antibody
and stained with FITC-goat-anti-mouse IgG.

In further experiments, we compared the ability of MDMX sumoylation mutants
to inhibit p53 transcriptional function. The MDMX mutants were cotransfected with p53
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expression plasmid and p53-responsive luciferase reporter into p53-null H1299 cells,
additionally, MDMX mutants were cotransfected with p53-luciferase reporter into p53wild type U2OS cells to determine the effect on endogenous p53 transcriptional activity.
In both tests, the MDMX sumoylation mutants exhibited similar ability to inhibit p53
function compared to wild type (data not shown). Coimmunoprecipitation experiments
with MDM2 and p53 also did not review changes in the ability of the sumoylation
mutants to bind MDM2 or p53 (Figure 38). Therefore, we concluded that sumoylation of
MDMX is not required for suppression of p53 activity under our experimental conditions.
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Figure 38. MDMX sumoylation status does not affect protein-protein
binding between p53, MDM2 and MDMX.
Wild type MDMX and MDMX sumoylation-deficient mutant were
cotransfected with MDM2 (lane 1-3) or p53 (lane 4-6) or both (lane 7-9) in
H1299 cells. No change of MDMX co-precipitated with MDM2 (compare
lane 2&3) or p53 (compare lane 5&6) was detected by Western blot with antiMDMX antibody 8C6. No change of MDM2 co-precipitated with p53 in the
presence of wild type or mutant MDMX was detected by Western blot with
anti-MDM2 antibody 3G9.

114

Discussion
In this report, we showed that similar to p53 and MDM2, MDMX also undergoes
modification by sumoylation. Conjugation to sumo-1 was detected both in vivo and in
vitro. Similar to other sumoylation substrates, MDMX sumoylation in vitro is highly
efficient in the presence of E1 and E2 enzymes, suggesting that a specific E3 is not
required for this reaction. Previous studies failed to identify the lysine residue important
for sumoylation on MDM2, possibly due to presence of multiple alternative sites
(Xirodimas, Chisholm et al. 2002; Chen and Chen 2003). Through deletion and point
mutagenesis, we were able to determine that K254 and K379 are important for MDMX
sumoylation. Single mutations on each site had limited effect on MDMX sumoylation,
but the double mutant largely abrogated the modification. Sequence comparison showed
that these sites are not conserved on MDM2, suggesting that MDM2 sumoylation
involves other lysine residues. Furthermore, mutation of K254 and K379 did not affect
MDMX ubiquitination, eliminating the possibility that sumoylation and ubiquitination
compete for the same lysines on MDMX.
An unresolved question is the role of sumoylation in the function and regulation
of the p53 pathway. Previous studies showed that sumoylation of p53 had very moderate
positive effects on its transcription activation function (Melchior and Hengst 2002).
Inability to identify the sumoylation site on MDM2 hampered investigation of the role of
this modification on MDM2 and p53 function. Generation of MDMX sumoylationdeficient mutants in this study enabled us to test whether sumoylation of MDMX is
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involved in several aspects of MDMX function and regulation. At present, the results
suggest that MDMX sumoylation is not required for MDMX ubiquitination and
degradation by MDM2. Furthermore, regulation of MDMX degradation and nuclear
translocation by DNA damage are not affected by lack of sumoylation. The regions of
MDMX that contain the sumoylation sites are not directly involved in binding to p53,
therefore it is not surprising that p53 binding and regulation by the MDMX mutants are
similar to wild type.
Comparison between the level of total MDMX expression in the transfected cells
and the amount of sumoylated MDMX recovered by His6-sumo-1 purification indicated
that only a small fraction of MDMX (<5%) is conjugated to sumo-1 at any given time.
Therefore, it is possible that the modification regulates a specific sub-population of
MDMX. Therefore, the impact of this modification on MDMX function may not be
evident by the overexpression assays we employed. Although the functional analysis so
far have not revealed a requirement for sumoylation in several aspects of MDMX
regulation, we cannot rule out a role for sumoylation in regulating other yet to be
identified MDMX functions. The findings and reagents described in this report should
facilitate future study of the role of sumoylation in regulating MDMX and the p53
pathway.
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Scientific Significance

P53 is a tumor suppressor serving as a guardian of the genome, and controls the
proliferation and apoptosis of abnormal cells. Under normal condition, p53 needs to be
maintained at low level to allow cell growth and proliferation. The two major negative
p53-regulators identified to date are MDM2 and MDMX.

In mouse models, the

abrogation of either MDM2 or MDMX lead to embryonic lethality, which can be rescued
by crossing into p53 null background, demonstrating that both MDM2 and MDMX are
major regulators of p53.
P53 is a well-known stress sensor for cells.

After DNA damage, p53

transcriptionally activates the downstream target genes such as p21 and Bax to stop the
cells carrying damaged DNA from proliferating or to eliminate the cells by apoptosis.
Hypothetically, full activation of p53 requires the inhibition of both MDM2 and MDMX,
which would restrain p53 activity under normal conditions. It is well recognized that p53
binding to MDM2 is weakened after DNA damage due to phosphorylation on the MDM2
binding site. However, the question still remains that if MDMX, the other major negative
regulator of p53 can be eliminated after DNA damage to allow the complete activation of
p53.
Since MDMX and MDM2 form heterodimers through their RING finger domains
and MDM2 contains the intrinsic ubiquitin E3 ligase activity, we speculated that MDMX
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might be an E3 substrate of MDM2. Indeed, we found that MDM2 can stimulate the
polyubiquitination and degradation of MDMX through the proteasome pathway. From
the in vivo and in vitro experiments, we concluded that MDM2 is the bona fide E3
ubiquitin ligase for MDMX and their heterodimerization through the RING domains is
required. Based on the fact that MDM2 accumulates due to p53 activation after DNA
damage and that MDMX can be degraded in an MDM2-dependent fashion, we
speculated that DNA damage might induce the degradation of MDMX partially through
the accumulation of MDM2. This was shown to true. After DNA damage, MDMX level
significantly reduced, which can be rescued by proteasome inhibitor. The reduction of
MDMX protein level is not caused by the mRNA change and is accompanied by the
accumulation of MDM2.
Interestingly, we found that ARF overexpression had a synergistic effect with
MDM2 in stimulating MDMX polyubiquitination and degradation. This is in contrast to
ARF’s inhibition of p53 polyubiquitination by MDM2.

Additionally, ARF

overexpression alone is sufficient in inducing MDMX degradation. This finding changed
our understanding of ARF from a stereotypical MDM2 inhibitor into a dynamic MDM2
E3 regulator, which turns on MDM2’s E3 function towards MDMX oncogene while
suppressing its E3 activity towards p53 tumor suppressor.
Based on the above findings, we proposed the following model: Under normal
condition, p53 remains inactive and unstable due to the negative regulation from both
MDM2 and MDMX. After DNA damage, MDMX is degraded through a proteasomedependent pathway.

Meanwhile, MDM2-p53 binding is disrupted due to p53

phosphorylation. On the other hand, oncogenic signals such as Ras and E2F1 can induce
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the overexpression of ARF, which stimulates MDM2 ubiquitination of MDMX
degradation and in the meantime, suppressing the ubiquitination of p53 by MDM2. Thus,
both DNA damage and mitogenic signals can activate p53 by abrogating the function of
both p53 negative regulators, namely MDM2 and MDMX. Our work established MDMX
as an important target of stress signals. Degradation of MDMX by MDM2 connects
MDMX to the well-established p53 signaling pathways and provides further insight into
the mechanisms of effective p53 response to stress (Figure 21).
Posttranslational modification is an efficient way to modulate protein biological
functions. We identified MDMX as an ubiquitin substrate of MDM2. Moreover, we
found that MDMX can be conjugated to SUMO-1 and identified the sumoylation sites on
MDMX to K254 and K379.

It is worth noticing that ARF can stimulate both

ubiquitination and sumoylation of MDMX. However, the mechanism through which ARF
modulates MDMX posttranslational modification remains elusive. In this manuscript, we
found that MDM2 significantly stimulates the binding efficiency between MDMX and
ARF. Additionally, ARF stimulates MDMX polyubiquitination in a dose-dependent
fashion associated with a stabilization of MDM2. Ongoing research in the lab is focusing
on the mechanism by which oncogenes signal through ARF to regulate MDMX function
and stability, as well as its implication on p53 activation. In conclusion, data from this
manuscript made important contribution to our understanding of the mechanism of
MDMX regulation, which is vital in understanding p53 activation upon DNA damage or
mitogenic stress.
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